Ropivacaine versus bupivacaine: characteristics and clinical aspects in lumbar epidural blockade by Kerkkamp, H.E.M.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/113888
 
 
 
Please be advised that this information was generated on 2018-07-08 and may be subject to
change.
eristics and clinical aspects in lumbar epidural blockad 
H E M . Kerkkamp 

Ropivacaine versus hupivacaine 

Ropivacaine versus bupivacaine 
characteristics and clinical aspects in lumbar epidural blockade 
Een wetenschappelijke proeve op het gebied van 
de geneeskunde en de tandheelkunde in het bijzonder de geneeskunde 
Proefschrift ter verkrijging van de graad van doctor aan de Katholieke Universiteit 
te Nijmegen, volgens besluit van het College van Decanen 
in het openbaar te verdedigen op woensdag 21 november 1990 
des namiddags te 3.30 uur 
door 
HANS EDDE MICHAEL KERKKAMP 
geboren op 8 maart 1956 te 's-Gravenhage 
Druk ssN, Nijmegen 1990 
promotor: Prof. Dr. L.H.D.J. Booij 
co-promotor: Dr. M.J.M. Gielen 
aan: Ella 
Pim 
Karlijn 
The research studies reported in this thesis were conducted at the Institute for 
Anesthesiology and at the CAOS/CAMM Center, University of Nijmegen, The 
Netherlands. 
Preparation of this thesis has been financially supported by: Astra Pain Control, The 
Netherlands. Stöpler, The Netherlands. 
CIP-DATA KONINKLIJKE BIBLIOTHEEK, DEN HAAG 
Kerkkamp, Hans Edde Michael 
Ropivacaine versus bupivacaine characteristics and clinical aspects in lumbar epidural 
blockade / Hans Edde Michael Kerkkamp. - [S.l. : s.n.] 
Thesis Nijmegen, 1990. - With summary in Dutch 
ISBN 90-9003677-6 
s i so 605.8 UDC 616-089.5 (043-3) 
Subject headings: ropivacaine/ bupivacaine/ local anesthetics 
No part of this book may be reproduced by any mechanical, photographic or electro-
nic process, or in the form of phonographic recording, nor may it be stored in a 
retrievalsystem, transmitted, or otherwise copied for public or private use, without 
the written permission of the author. 
Omslagontwerp en boekverzorging: Anky ter Веек, [ .тв] 
ISBN 90 9003677 6 
Acknowledgements 
I would like to thank everyone who helped me in completing this thesis, especially: 
Prof.Dr.L.H.D.J. Booij, promotor, for his encouragement and advice during the 
completion of this thesis. 
Dr.M.J.M. Gielen, co-promotor of this thesis, my guide in regional anesthesia. He 
stimulated me in the research concerning local anesthetics and helped me in perform-
ing the clinical studies. 
Dr.H.J. Bruins Slot, who gave me clear insight into the X-ray diflfraction techniques 
and scientific and moral support. 
Dr.R. Dirksen, Miss E van de Pol and Miss W. Janssen for their contributions in the 
development of the animal model. 
The staff members and residents of the Institute for Anesthesiology, for providing the 
facilities to complete this thesis. 
The operating personnel at the urology theaters for their patience and cooperation. 
The patients for their consent to participate in the studies. 
The Astra company for their scientific support and assistance in calculating the statis-
tics. 
Dr. H. Bakker for linguistic corrections of the manuscript. 
Finally I thank my wife Ella for her patience and tender support. 

Contents 
1 
Aims and objectives of the studies π 
2 
Local anesthetics 15 
3 
Crystal structure determinations of the local anesthetics ropivacaine and bupivacaine 2p 
4 
Cardiovascular effects of epidural blockade 4p 
5 
Noninvasive hemodynamic monitoring by thoracic bioimpedance 57 
6 
Hemodynamic monitoring in epidural blockade: cardiovascular effects of 20 ml 0.5% 
bupivacaine with and without epinephrine dy 
7 
Cardiovascular effects after lumbar epidural administration of 0.75% bupivacaine 
and 0.75% ropivacaine, both with epinephrine 77 
8 
Effects of epidurally and intrathecally administered ropivacaine and bupivacaine in 
rats pi 
9 
An open study comparison of 0.5%, 0.75% and 1.0% ropivacaine, with epinephrine, 
in epidural anesthesia in patients undergoing urologie surgery 105 
10 
Comparison of 0.75% ropivacaine with epinephrine and 0.75% bupivacaine with 
epinephrine in lumbar epidural anesthesia щ 
Summary and conclusions 12$ 
Samenvatting en conclusies 12p 
Curriculum vitae 131 

CHAPTER I 
Aims and objectives of the studies 

The lumbar approach to the epidural space was first described by the Spanish surgeon 
Fidel Pages (1921). Its main attractions over the spinal blockade arc that it never causes 
headache and that it allows the possibility of extending the sensory blockade into the 
postoperative period, either by repeated injections or by continuous infusion. 
Several local anesthetics are used for epidural anesthesia. Today the most used 
drug is bupivacaine, especially for postoperative pain relief. However accidental intra-
venous injection of bupivacaine may cause sudden cardiovascular collapse (Albright 
1979, Moller 1988). To ensure safe and optimal perioperative treatment new drugs 
have been introduced. 
The development of local anesthetic drugs is facilitated by molecular engineering. 
Differences in chemical structure of the various compounds relate to anesthetic prop-
erties. The determination of crystal structures of closely related drugs is used to 
understand and explain the phenomenon that minor changes in structural formula 
may cause severe differences in physiochemical characteristics. 
Ropivacaine, n-propyl-i-dimethyl-2',6'-piperidine-carboxanilidine-2, is the latest 
long acting local anesthetic agent of the amide type. Animal studies have indicated 
that ropivacaine is less cardiotoxic than bupivacaine (Akerman 1988). The cardiovas-
cular effects of local anesthetics can be studied by invasive monitoring. The risks asso-
ciated with this kind of monitoring pose a significant hazard to the research patient. 
Noninvasive assessment of cardiovascular function offers the anesthesiologist tech-
niques that limit the risks. 
This thesis covers the above mentioned aspects of the local anesthetics bupivacaine 
and ropivacaine. The main objectives of this thesis are: 
- To determine the crystal structure of ropivacaine and bupivacaine (chapter 3). 
- To assess the cardiovascular effects of addition of epinephrine to bupivacaine for 
epidural blockade (chapter 6). 
- To assess cardiovascular effects after epidural injection of either ropivacaine or 
bupivacaine (chapter 7). 
- To determine the dose-response relationship after epidural or intrathecal injection 
of ropivacaine and bupivacaine in rats (chapter 8). 
- To evaluate the clinical efficacy of ropivacaine in different concentrations for epi-
dural anesthesia (chapter 9). 
- To evaluate the differences in neural blockade characteristics of ropivacaine and 
bupivacaine following epidural administration in humans (chapter 10). 
These studies are accompanied with brief surveys of the general pharmacology and 
neurophysiology of local anesthetics, the method of noninvasive cardiovascular moni-
toring by thoracic electrical bioimpedance and the cardiovascular effects of epidural 
blockade (chapter 2, 4 and 5). 
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CHAPTER 2 
Local anesthetics 

History of ester type local anesthetics 
The first local anesthetic discovered was cocaine, an alkaloid extracted from the coca 
plant. The Incan people thought that the coca leaf was a gift from their Sun God, 
Manco Сарае (Gay 1976). The leaves were initially used among the religious and po­
litical aristocracies of Incan society. After the destruction of Incan civilization in the 
sixteenth century, the lower classes and slaves were paid in coca leaves. Coca served as 
a stimulating tonic to the people working in the Andes. 
In i860 Albert Niemann (1834-1861) isolated cocaine from the leaves of 
Erythroxylon coca (Niemann i860). Von Anrep reported the physiologic and phar­
macologic effects of cocaine in an extensive article (Anrep 1880). Large doses of this 
alkaloid, administered in warm blooded animal, caused psychic agitation and excita­
tion, acceleration of respiration and heart rate, a rise in blood pressure and dilatation 
of pupils. 
Karl Koller, a resident in ophthalmology, was intent upon finding a drug to anes­
thetize the cornea. In 1884 he was the first person to use the drug for topical anesthe­
sia in the human eye (Koller 1884). James Leonard Corning (1885), a neurologist, was 
the first who used cocaine to generate a central neural blockade (epidural). 
The strong toxicity, the short duration of anesthesia and the impossibility of steri­
lizing the solution, stimulated chemists to find a substitute which was free of these 
disadvantages. Cocaine in high doses produces tremors, seizures, tachycardia, vaso­
constriction, and elevation of body temperature. 
Presumably around 1904, Einhorn synthesized procaine. This drug was the first 
synthetic ester type local anesthetic. Procaine was found to elaborate few central nerv­
ous effects. Following the introduction of procaine, numerous ester type local anes­
thetics were synthesized. Tetracaine, the most potent ester of the benzoic acid series, 
was synthesized in 1928 by Eisler. The least toxic ester type local anesthetic, chloro-
procaine, was discovered in 1949. The major drawback to these drugs has been, un­
fortunately their propensity for producing allergic reactions. 
History of amide type local anesthetics 
The first amide type local anesthetic was discovered by Meischer (1932) in 1925. 
Dibucaine was extremely potent and highly toxic. It was discovered while preparing 
an antipyretic agent related to quinine. In 1935, two Swedish chemists, von Euler and 
Erdtman, tried to elucidate the structure of an alkaloid, gramine. In the course of the 
investigations they synthesized a compound which was isomeric with gramine but, as 
opposed to gramine, exhibited a local anesthetic action. Other related compounds, 
the so called alkylaminoacylanilides, were synthesized by Erdtman and Löfgrcn. 
From subsequent investigations Löfgren and Lundqvist discovered, in 1943, the 
compound diethylaminoaceto-2,6,-xylidine (figure 2.1), which today is known as 
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lidocaine (Löfgren 1948). This local anesthetic was more stable in solution, had a 
shorter onset of sensory blockade and a longer duration of action, than the amino 
ester agents. The amide type local anesthetics proved to be less allergenic than the 
ester type anesthetics (Incaudo 1978, DeShazo 1979, Brown 1981, Fisher 1982). 
/ — ( H 0 с 2 н 5 
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Figure 2.1: The chemical formula of lidocaine, showing the three essential portions of a local anesthetic 
molecule. 
Although the clinical profile of lidocaine (relatively fast onset, good sensory and 
motor blockade, low toxicity) was satisfactory, its duration of action was short. So the 
need for a long-acting local anesthetic was the main reason for further research. A 
large part of the initial clinical investigations of bupivacaine was performed by 
Widman (1964). Table 2.1 gives the chronology of some ester type and amide type 
local anesthetics, including the years of synthesis and clinical application. 
Even with the wide range of agents, there is a need for more safety, versatility, and 
other modes of use of local anesthetics. Over the past two decades sudden cardiovas­
cular collapses have been reported after accidental intravenous injection of a large 
dose of bupivacaine in patients (Albright 1979). This indicates the need for the de­
velopment of an equally effective, but less toxic local anesthetic agent. 
Chemical structure of local anesthetics 
Local anesthetics are chemicals which consist of a lipophilic and hydrophilic portion 
separated at a distance of 6 to 9 Angstroms by an intermediate chain (figure 2.1). The 
total length of the molecules varies between 13-18 Angstroms. The hydrophilic group 
is usually a tertiairy amine, while the lipophilic portion is usually an unsaturated aro­
matic ring such as para-aminobenzoic acid. The intermediate chain contains either an 
ester (-COO) or an amide (-CONH) linkage. Local anesthetics therefore are classi­
fied as ester or amide compounds. Ester type agents include cocaine, benzocaine, pro­
caine, chloroprocaine and tetracaine; while amide type agents include dibucainc, 
lidocaine, prilocaine, etidocaine, mepivacaine, bupivacaine, articaine andropivacaine 
(figure 2.2a/b) (Tucker 1988). Ropivacaine and bupivacaine are structurally related: 
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the former is the active (L) form of i-propyl-2/,6'pipecoloxylidide) and the latter is 
racemic (DL) i-butyl-2',6'-pipecoloxylidide. 
Table 2.1' Chronology of local anesthetic agents. 
Drug Year 
of synthesis 
Esters 
Cocaine 
Benzocame 
Procaine 
Tetracaine 
Chloroprocame 
Amides 
Dibucame 
Lidocame 
Mepivacame 
Pnlocame 
Bupivacame 
Et idocame 
Ar t icame 
Ropivacame 
' N i e m a n n 1860 
2Kol ler 1884 
3Sall<owski 1895 
4Einhorn 1899 
*No t known 
1860 
1895 
1904 
1928 
1949 
1925 
1943 
1956 
1959 
1957 
1971 
1974 
1957 
Discovered by 
N iemann 1 
Salkowski 3 
Einhorn 4 
Eisler 
Marks 
Meischer9 
Lofgren 7 
Ekenstam 8 
Lofgren 9 
Ekenstam 8 
Takman 
Muschaweck 1 1 
5Braun 1905 
6Meischer1932 
7Lofgren 
8E ken sta 
1948 
m 1957 
Ekenstam 8 
9Lofgren 1960 
1 0 Widman 1964 
Clinical 
in t roduct ion 
1 1Muschaweck1974 
1 2Bader1974 
1884 
1904 
1905 
1932 
* 
1930 
1947 
1957 
1960 
1963 
1972 
1974 
1988 
" T h e f irst 
Clinical use 
Koller2 
Einhorn 4 
Braun 5 
* 
* 
Uh lmann 
Gordh 
Dhuner 
Wie ld ing 
W i d m a n 1 0 
Lund 
Bader12 
Kerkkamp1 3 
epidural inject ion of 
ropivacame in 
24th february 
the Umvei 
N i jmegen, 
humans was on 
1988 at 
•sity Hospital of 
, The Nether lands 
Physicochemical properties 
Small changes in the chemical structure of local anesthetics produce profound 
changes in physicochemical properties and in clinical profile. Differences in phar-
macology of local anesthetics such as onset, duration of action and potency are asso-
ciated with physical and chemical properties (Concepción 1984). Duration of action 
is related to protein binding and lipid solubility. The lipid solubility also determines 
the intrinsic anesthetic potency. 
Molecular weight 
The molecular weights of the amide type local anesthetics vary from 220-325. The 
molecular weight determines the rate of diffusion into the sodium channel of the 
nerve membrane (Courtney 1980). Transdural transfer is also dependent on molecu-
lar weight. 
Structure-activity relationships in series of homologous local anesthetics were 
studied by Âberg (1977). He demonstrated that when the number of carbon atoms on 
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the piperidine-nitrogen of the mepivacaine molecule was increased to up to four or 
five carbons, the toxicity of the compounds and the duration of their local anesthetic 
effects were increased. 
Esters 
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Figure 2.2a: Chemical structures of currently available ester type local anesthetic agents. 
Lipid solubility 
The lipophilic portion of the molecule is essential for anesthetic activity. A high lipid 
solubility would be expected to promote diffusion through membranes, thereby de­
creasing the onset time of action, and to enhance interaction with hydrophobic com­
ponents of receptor sites. 
Therapeutically useful local anesthetics require a delicate balance between lipid 
solubility and water solubility. Partitioning between η-heptane and phosphate buffer 
(pH 7.4 at 370C) is often referred to when comparing the lipid solubilities of local 
anesthetics (Tucker 1980). Investigations of the relative partitioning of four amide 
local anesthetics (see table 2.2) in n-heptane/phosphate buffer, rat sciatic nerve tissue, 
human extradural fat and human subcutaneous fat showed that the ratios of relative 
mean uptake of bupivacaine and ropivacaine were lower than the theoretical n-heptane/ 
Amides 
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Figure 2.2b: Chemical structures of currently available amide type local anesthetic agents. 
buffer ratios (Rosenberg 1986). The variation in the absorption of bupivacaine and 
ropivacaine into fatty tissues is much less than in n-heptane/phosphate buffer. 
Therefore the solubility in a pure organic solvent is not an optimal predictive test of 
clinical differences between local anesthetics. 
Table 2 2- Ratios of relative partitioning and mean relative uptake of four amide local anesthetics in a pure 
organic solvent and in biological tissues 
Β E L R 
n-Heptane/phosphate buffer 10 0 39 0 1 2 9 
Human extradural fat 4 1 8 3 1 2 3 
Human subcutaneous fat 3 8 10 6 1 19 
Rat sciatic nerve 3 3 4 0 1 2 3 
В =bupivacaine E =etidocaine 
L=lidocaine R =ropivacaine 
From Rosenberg (1986) 
pKa 
The pKa of a compound determines the extent of ionization. The greater the pKa of a 
base, the smaller the fraction of nonionized compound at any pH. Because the non-
ionized form of the agent is responsible for diffusion across the nerve shear and mem­
brane (Ritchie 1965), the pKa values of local anesthetics are related to the onset of 
anesthesia. 
The esters have higher pKa values (8.46-9.05) than the amides (7.76-8.16) and 
will, therefore, be less ionized at physiological pH (7.4). To ensure the stability of the 
ester-type agents they are dispensed in acid solutions. Hence the pH of plain ester so­
lutions is low (2.8) compared with the pH of the amides (4.4-6.4). Consequently a 
less nonionized ester drug is available initially to diffuse to action sides. 
Protein binding 
The degree of protein binding has important pharmocokinetic and pharmoco-
dynamic implications. A high degree of binding to plasma and tissue proteins of a 
local anesthetic exhibits a high potency and long duration. 
The two plasma proteins that bind amide local anesthetics are αϊ-acid glycopro­
tein and albumin (Routledge 1980). (Xi-Acid glycoprotein has a high affinity for local 
anesthetics, but has a limited capacity, whereas albumin has a low affinity but a large 
capacity. 
Metabolism 
The ester compounds are metabolized in blood and the liver. They are hydrolyzed by 
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pseudocholinesterases. Plasma half life times in normal adults vary from 10-20 se­
conds for chloroprocaine to several minutes for tetracaine (Foldes 1965, O'Brien 
1979). The clinical implication of the rapid clearance of esters is that if a toxic concen­
tration is attained after accidental intravenous injection, the ensuing reaction is of 
short duration. 
The amide type local anesthetics are stable in blood. The metabolism of amide 
types is more complex and slower; these drugs undergo varying rates of metabolism 
by microsomal enzymes located primarily in the liver (Boyes 1975, Covino 1976). The 
rate of hepatic degradation varies between the compounds. Plasma half life times vary 
from 93-96 minutes for prilocaine and lidocaine to ш-162 minutes for ropivacaine 
and bupivacaine (Lee 1989). Table 2.3 summarizes the physicochemical properties of 
local anesthetics. 
Table 2 3 Physicochemical properties of local anesthetics 
Agent Mol 
Esters 
Procaine 
Chloroprocaine 
Tetracaine 
Amides 
Lidocaine 
Prilocaine 
Mepivacame 
Etidocame 
Bupivacaine 
Ropivacaine 
weight (Base) 
236 
271 
264 
234 
220 
246 
276 
288 
274 
Pka1 
9 05 
8 97 
8 46 
7 91 
7 90 
7 76 
7 70 
8 16 
8 07 
Partition coeftitient2 
0 02 
0 14 
4 1 
29 
0 9 
0 8 
141 0 
27 5 
87 
Percent plasma3 
protein binding 
6 
* 
76 
64 
55 
77 
94 
95 
85 
1At 250C 
2n-Heptane/phosphate buffer (цд ml'Vpg ml"') at 370C, pH 7 4 
3The percentage binding relates to concentrations of a drug around 1 μg local anesthetic ml"1 plasma (Tucker 
1975) 
* Not known 
Mechanism of action 
Local anesthetics interfere with the conduction of action potentials along the pe­
ripheral nerve fibers. They generally do so by impairing the function of sodium chan­
nels within the region where the drug has been applied (Strichartz 1973). 
Resting membrane potential 
Nerve fibers possess a lipoprotein membrane that separates the intracellular matrix 
from the extracellular phase. An electrolyte concentration gradient between the intra­
cellular fluid, containing mainly potassium, and the extracellular fluid, containing 
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sodium, is maintained by an active metabolic process. The concentration gradient for 
potassium is the major determinant of the transmembrane potential (-70 to -90 mV). 
The membrane is polarized. The resting potential exists because there are more 
anions than cations within the cell. The high extracellular sodium concentration is 
maintained because at rest the membrane is impermeable to sodium ions (Guyton 
1986). 
The nerve action potential 
Nerve signals are transmitted by action potentials, which are rapid changes in the 
transmembrane potential. The membrane suddenly becomes permeable to sodium 
ions, allowing the migrations of sodium ions to the interior of the axon and of potas-
sium to the outside. This is called depolarisation. The normal rest potential of-70 to 
-90 mV is lost, with the potential rising rapidly in the positive direction (+20 mV). 
This is quickly followed by repolarization back to the resting value. The process occu-
pies 1-2 ms. The principal actor in causing depolarization of the nerve membrane 
during the action potential is the voltage-gated sodium channel. The channels con-
tain charged or dipolar regions that slide, twist or turn when changes in the mem-
brane's electric field (corresponding to the transmembrane potential) alter the energy 
differences between different conformations of the channel. Through such "voltage-
gated" changes in shape, ion channels are "activated" to ion-conducting (open) states 
by membrane depolarization (Catterall 1988). The depolarizing phase of impulses fol-
lows from the activation of Na* channels and the resulting flow of Na* ions into the 
cell (Hodgkin 1952). 
The voltage change associated with the depolarizing phase opens the sodium 
channels in the next section, so that the action potential is propagated along the nerve 
(Guyton 1986). 
Site of action of local anesthetics 
Local anesthetics act by interfering with the ability of the membrane to undergo the 
specific change in permeability to sodium in response to partial depolarization. Three 
distinct sites have been proposed where local anesthetics might exert their effect on 
sodium conductance (Seeman 1972, Ritchie 1975, Lee 1976): 
1 On the membrane surface, involving alteration of the fixed negative charge and 
hence transmembrane potential, without change in resting intracellular potential. 
2 Penetrating the membrane, to cause a conformational change in lipoproteins, 
thereby causing distortion of the sodium channel. 
3 Binding to specific intracellular receptors at the cell membrane and preventing the 
opening of sodium channels. 
During the past decade much evidence has accumulated to support the specific recep-
tor binding hypothesis(Hille 1980). Nevertheless, the membrane distortion theory 
still provides part of the explanation for anesthetic actions. 
M 
Differential blockade 
The ability of local anesthetics to block impulse conduction in certain nerve fibers, 
while sparing conduction in others, has generated much attention. This situation is 
called a differential block. This term, when defined as selective block of specific nerve 
fibers, implies that motor and sensory characteristics depend on activity in specific 
nerve fiber groups. 
Nerve fibers are classified as A, B, and С fibers, on the basis of their diameters and 
velocity of conduction of nerve impulses (table 2.4). The diameter and myelinization 
of a nerve fiber determine its sensitivity to local anesthetics (Wildsmith 1975). 
Bupivacaine and etidocaine provide an interesting contrast in terms of their difiFer-
ential sensory/motor blocking activity, although they are both potent long acting 
anesthetics (Scott 1980). Bupivacaine is widely used to provide adequate sensory anal­
gesia with minimal blockade of motor fibers. On the other hand etidocaine shows lit­
tle separation between sensory and motor blockade. 
The factors responsible for differential sensory/motor separation are not known 
precisely. The concept that the small myelinated fibres are more susceptible than the 
larger fibres to be blocked by local anesthetics has been questioned and a reverse fiber 
sensitivity was found in animal nerves (Gasser 1929, Gissen 1980). The slow blockade 
of A-fibcrs by bupivacaine is believed to be a result of the relatively high pKa of this 
agent. Other factors found to modulate the degree of blockade include: temperature, 
pH, nerve activity, nerve type, duration of drug exposure, C 0 2 tension, and so forth 
(Raymond 1987). 
Table 2.4 Classification of peripheral nerve fibers. 
Fibre type 
A- alpha 
beta 
gamma 
delta 
В 
С 
Diameter 
(μιη) 
12-20 
5-12 
3-6 
2-5 
<3 
0 3-1 3 
+++ heavily myelinated 
+ lightly myelinated 
Myelin 
+++ 
+++ 
++ 
++ 
+ 
• 
Conduction speed (ms"1) 
70-120 
30-70 
15-30 
12 30 
3-15 
0 5-2 3 
++ moderately myelinated 
- nonmyelinated 
fast pa 
Function 
somatic motor 
touch, pressure 
proprioception 
in, touch, temperature 
preganglionic autonomic 
slow pam, reflexes, temperature 
Conclusion 
The most important clinical properties of local anesthetic agents are potency, onset, 
duration of action and relative blockade of sensory and motor fibres. These qualities 
are related to physicochemical characteristics of the drugs. On the basis of anesthetic 
activity in man the agents are classified as follows: 
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ι Low anesthetic potency and short duration of action: procaine and chloroprocaine. 
2 Intermediate anesthetic potency and duration of action: lidocaine, mepivacaine, 
prilocaine. 
3 High anesthetic potency and prolonged duration of action: tetracaine, etidocaine, 
bupivacaine and ropivacaine. 
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Introduction 
A prerequisite for the complete physicochemical interpretation of the processes in­
volved in neural blockade by local anesthetics is, that the structures of the appropriate 
components be known to atomic detail 
From the structure/activity relationships obtained by Aberg and others (1977), it 
appears that by increasing the number of carbon atoms on the pipendine nitrogen on 
the mepivacaine molecule, the physicochemical and biological effects of these amide 
type local anesthetics are changed Since the theory of the action of local anesthetics 
is, at present, not unambiguously determined (Hille 1980, Stnchartz 1987), the need 
for 3-dimensional information of both local anesthetics and the excitable tissues is put 
forward The axonal membrane is similar to the plasma membrane of other cells, and 
is complex and comprise many different molecules such as, carbohydrates, proteins 
and lipids 
X-ray crystallography is the most powerful method of deriving structure informa­
tion This chapter, starting with a brief summary on the basic principles of X-ray dif­
fraction by single crystals, deals with the elucidation of the 3-dimensional structure of 
the active forms of both ropivacaine and bupivacaine The 3-dimensional structures 
of the molecules of the excitable cell membrane remain to be determined to clarify 
the mechanism of action. 
X-ray diffraction 
A single crystal can be thought of as a three dimensional repeating pattern of identical 
units, the so called unit cells. A unit cell is described by three base vectors, a, b and с 
Because of its three dimensional grating, a single crystal diffracts X-rays in discrete di­
rections Each diffracted beam is called a reflection h, and its direction is related to 
the reciprocals of the three base vectors of the unit cell A physical explanation of the 
diffraction of X-rays was given by W L Bragg in the second decade of this century 
(Bragg 1913) He showed that the diffracted beams behave as if they are reflected from 
discrete planes passing through the crystal lattice Intensity maxima are only observed 
when angle of the incident X-ray with a set adjacent planes obey Bragg's law (figure 
31)· 
2dhSin(6)=nX (3.1) 
From X-ray diffraction theory it follows that the intensity I of a reflection h, is pro­
portional to the squared amplitude of a complex quantity known as the structure fac­
tor F h . 
Ih = constant IFhl' (3.2) 
31 
When the atomic structure of the crystal is known, the structure factor Fj, can be cal­
culated from 
N 
Fh= Σ fj.h explzjiih.r,] (3.3) 
where N is the number of atoms in the unit cell, fj^ is the atomic scattering factor of 
atom j for reflection h, and г is the position of atom j . If the atomic structure of the 
crystal is represented by a continuous electron density function a(r), its periodicity 
allows c(i) to be written as a Fourier series: 
a ( r ) = V-1 XFhCxpt-zTtih.r] (3.4) 
h 
where V is the volume of the unit cell and г is the position of a point in the unit cell. 
Thus, if structure factors Fj, arc known, a(r) can be calculated directly, and the 
three dimensional arrangement of atoms in the unit cell can be obtained. 
Unfortunately, the complex structure factors Fj, are known only in magnitude from 
equation 3.2; their phases are unknown. This is the 'phase problem' in crystallog­
raphy. Each method to solve a structure by X-ray diffraction data involves finding the 
phases of structure factors. Once phases are found, the electron density function is 
calculated using equation 3.4, and from its local maxima the arrangement of atoms in 
the unit cell can be deduced. 
Figure ).i.-Two waves are incident on the h set of planes. A phase difference between the two waves exists 
and an intensity maximum occurs if the geometrical path difference (AB+ ВС = 2 dh sin (Θ) between the 
waves is an integral number of wavelengths (η.λ). 
X-ray structure determination 
Raw material for both (i) n-propyl-i-dimethyl-2', 6'-piperidine-carboxanilide-2-
(ropivacaine) and (2) n-butyl-i-dimethyl-2',6'-piperidine-carboxanilide-2 (bupiv-
acaine) was supplied by Astra Alab, Södertälje, Sweden. Only for (1) a diastereomeric 
salt was provided. Recrystallization from 1:1 ethanol/water (1) and from 1:1 
ethanol/acetone (2) yielded needle-shaped crystals. Datasets were collected on an 
32 
Enraf-Nonius CAD-4 diffractometer using graphite monochromatized CuKot radia­
tion (λ=ι.54ΐ84Α) using the (О-г scan technique ( o ^ θ <700) with a scan angle of 1.50 
and a variable scan rate with a maximum scan time of 20s per reflection. Profile analy­
sis was performed on all reflections (Lehman 1974, Grant 1978). Normal Lorentz-
polarization corrections and empirical absorption corrections using psi-scans (North 
1968) were applied. Crystal data and experimental data are summarized in table 3.1. 
As opposed to the straightforward data collection on bupivacaine (2), the crystals of 
ropivacaine (1) appeared to be twinned. From CAD-4 data collected to determine the 
Table 3 1 Crystal and experimental data 
Structural formula 
M r 
Crystal system 
Spacegroup 
a (À) 
b(A) 
с (A) 
an 
volume (À3) 
Ζ 
D x (gem"3) 
radiation (À) 
μ (cm"1) 
F(000) 
T(K) 
Crystal dimensions (mm) 
Ropivacaine 
C17H27N20+CI H20 
328 861 
monoclmic 
P2i 
9 5508(14) 
7 3287(6) 
13 1784(7) 
97 429(15) 
914 7(2) 
2 
1 194 
aCuKa)=1 54184 
19 23 
355 95 
293 
0 19x0 18x0 07 
No of reflections to determine lattice parameters 25 
θ range Π 
Мах(зіп( )Л)(Л_ 1) 
hkl range 
h 
к 
I 
No of standard reflections 
Drift correction range 
Emp abs correction range 
Total data measured 
Unique data 
Rint=I(l <Ι>)/ΣΙ 
Data used in refinement 
Parameters refined 
R 
R w I * W(F)+gF 2 ] 
S 
Weighting-scheme parameter g 
Max shift/error in last cycle 
Final difference Fourier map peaks (еА'э) 
mm 
max 
19 35 
0 588 
-11,11 
8,8 
-15,15 
3 
1031 0 981 
1 000-0 897 
6206 
1688 
0 023 
2062 
189 
0 056 
0 053 
0 294 
0 001 
0015 
-0 27 
0 23 
Bupivacaine 
C18H29N20+CI гСгНбО 
347 927 
monoclmic 
ΡΣ,/η 
9 220(3) 
110417(17) 
20 392(6) 
102 85(4) 
2024(1) 
4 
1 142 
aCuKa)=1 54184 
17 43 
755 89 
293 
0 48x0 22x0 18 
25 
20 35 
0 609 
-11,11 
0,13 
-24,24 
3 
1 120-0 989 
0 999 0 894 
8082 
3827 
0 017 
2318 
244 
0 064 
0 069 
2 805 
0 004 
0 084 
-0 30 
0 45 
33 
unit cell dimensions it appeared that the two indiviuals (I and II) of the crystal share 
their ab plane. The twinning operation is the reflection in this ab plane. The resulting 
angle between a,* and ац* is 165.14(2)° Fig. 3.2 shows the hoi zone, in which indices 
for both lattices are given. Reflections with h=o coincide for the two lattices. Again, 
there is a hypothetical coincidence for h=2.8, therefore the reflections зп,к,1 are ex­
cluded from the least-squares refinement. 
• . •α ·α ·ο «α -α -α «α -a a a 
• · η · ο · D" π · π · π · α · π · α α 
306 30S 304 ЭОЭ 302 301 300 
• a о a _ a <з _ о _ а с с _а 
306 305 304 303 302 301 300 
206 205 204 203 202 201 200 
о · α · α · а - о - π - α * α · _ α · _ α 
206 205 204 203 202 201 200 
106 105 104 103 102 101 100 
- а - о · α · ο - а > а - о · о - о _.• о 
Ϊ06 105 Ϊ04 103 102 «j \ 
006 005 004 003 002 
• • • · • • • • 
006 005 004 003 002 
Figure 3.2: Indexed hOl zone of (ι) ropivacaine. (For individual I, points with indices given above: for in­
dividual 11, squares with indices given below). 
The structures were solved using the automated Patterson search methods of the 
DIRDIF system (Beurkens 1984, Beurkens 1987). For the orientation and translation 
searches the non-hydrogen fragment depicted in fìg.3.3 was used. Coordinates for this 
fragment were obtained from molecular mechanics calculations using MacroModel 
(Mohamadi 1990). In the DIRDIF Fourier synthesis, all non-hydrogen atoms for 
both (1) and (2) were found. The structures were refined isotropically. 
The phenyl groups were treated as regular hexagons, with C-C distances of 1.395Â. 
During the isotropic refinement, a peak in the difference Fourier map was assigned a 
water oxygen (O2) for ropivacaine, and three peaks in the difference Fourier map of 
bupivacaine were assigned C19 with full occupancy, and C20 and О21 with half occu­
pancy, to form disordered acetone. Η atoms were located from subsequent difference 
Fourier maps. Η positions were refined with fixed isotropical temperature factors, 
which were taken from the atoms they are bonded to. Except the Η atoms bonded to 
34 
Ν, the Η atoms were refined, riding on the atoms they are bonded to. No positional 
parameters for the ammo proton H i in ropivacaine (i) could be obtained. Isotropic 
refinement of H i , placed at a calculated position, using 'riding mode' resulted in an 
unacceptable large temperature factor, and therefore H i was omitted. No hydrogen 
atoms could be located for the solvent molecules in both structures. After an addi­
tional empirical absorption correction using DIFABS (Walker 1983), the nonhydro-
gen atoms were refined anisotropically, except for the solvent molecules which were 
refined isotropically. 
At this stage an examination of the temperature factors of the atoms C19, C10 and 
O n revealed that the initial assignment was not correct and that a description as dis­
ordered ethanol with occupancies of 1., 0.15 and 0.15 for the renamed atoms C19, 
O10 and O n respectively, was more appropriate than disordered acetone. Isotropic 
refinement of this model with fixed site occupancy factors showed a consistent set of 
temperature factors. 
О N + ' 
/ 
Figure s } Non-hydrogen skeleton used for orientation and translation searches of the DIRDIF system. 
The H atoms of the methyl groups in (1) appeared to be disordered. From a diffe­
rence Fourier map alternative positions for the methyl H atoms were located. Of all 
methyl H atoms, the positional parameters and the site occupancy factors were re­
fined with fixed isotropical temperature factors using distance constraints. For refine­
ments and as a source of atomic scattering factors, SHELX (Sheldrick 1976) was used. 
The absolute configuration of (1) was confirmed using BIJVOET (Beurskens 1980), 
B=o.9933(3). Positional parameters for all atoms are given in table 3.1 for both (1) and 
(2).* 
*Lists of structure factors, complete lists of positional and (an)isotropic thermal parameters and full lists 
of bond lengths, angles and torsion angles have been deposited with the British Library Document 
Supply Centre as Supplementary Publication Copies may be obtained through The Executive Secretary, 
International Union of Crystallography, 5 Abbey Square, Chester CI h 2IIU, England 
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HI 
H2 
НЗ 
Н4 
Н5 
Н71 
Н72 
Н73 
Н74 
Н75 
Н76 
Н81 
Н82 
Н83 
Н84 
Н85 
Н86 
НЮ 
H i l l 
Н112 
Н121 
Н122 
Н131 
Н132 
Н141 
Н142 
Н151 
Н152 
0 3219(20) 
-0 736(5) 
0 762(4) 
0 712(4) 
-0 5729(3) 
0 8925(3) 
-0 8065(3) 
0 6487(3) 
-1 0212(3) 
0 4420(3) 
-0 4305(6) 
0 992(8) 
-0 4920(6) 
1 029(7) 
-0 5099(6) 
1 029(9) 
1 003(8) 
-
1 063(6) 
0 973(8) 
-1 0134(5) 
0 464(10) 
-1 0950(5) 
0 392(13) 
1 1110(5) 
0 355(10) 
0 435(7) 
0 344(3) 
0 429(7) 
-0 7824(4) 
0 7716(3) 
-0 5732(4) 
0 9640(4) 
-0 5325(4) 
1 0093(4) 
-0 5976(4) 
1 1146(5) 
-0 4706(4) 
1 0056(5) 
-0 6676(4) 
0 9525(5) 
-0 6523(4) 
0 9261(5) 
0 8983(4) 
0 6948(5) 
-0 8587(4) 
0 7437(5) 
1 0570(4) 
0 5025(4) 
-1 0091(4) 
0 4830(4) 
-0 0895(17) 
0 198(7) 
-0 048(4) 
0 080(4) 
0 0665(5) 
0 2073(2) 
0 0170(5) 
0 2779(2) 
0 0028(5) 
0 2324(2) 
0 1076(10) 
-0 004(4) 
0 0083(10) 
0 140(7) 
0 2307(10) 
0 080(9) 
0 084(11) 
0 118(7) 
-О 009(3) 
0 0582(6) 
0 101(17) 
0 0881(6) 
0 029(8) 
0 1505(6) 
0 173(9) 
0 163(7) 
0 127(8) 
0 022(2) 
0 1690(5) 
-0 1026(3) 
0 1438(8) 
0 0983(4) 
0 0784(8) 
0 0152(4) 
0 2046(6) 
0 0342(4) 
0 0312(6) 
0 1480(4) 
0 0091(6) 
0 0804(4) 
-0 1855(6) 
0 0570(4) 
0 0972(6) 
0 0380(3) 
0 1238(6) 
-0 1488(3) 
0 1711(6) 
0 0477(3) 
0 1567(6) 
0 0260(3) 
0 9851(9) 
0 342(3) 
0 635(2) 
0 821(2) 
-0 6649(1) 
0 4675(1) 
0 7663(1) 
0 4150(1) 
0 6796(1) 
0 4641(1) 
0 5076(4) 
0 601(5) 
0 4047(4) 
0 615(5) 
-0 4152(4) 
0 541(3) 
0 631(5) 
0 563(5) 
0 567(6) 
0 3955(4) 
0 625(9) 
0 4917(4) 
0 555(8) 
-0 5064(4) 
0 562(8) 
0 614(3) 
0 538(2) 
0 589(4) 
0 1812(3) 
0 7398(2) 
-0 1444(3) 
0 7926(2) 
-0 1827(3) 
0 7498(2) 
-0 0235(3) 
0 8676(2) 
0 0050(3) 
0 8390(2) 
0 1089(3) 
0 9394(2) 
0 0323(3) 
0 9094(2) 
0 0263(3) 
0 9028(2) 
-0 0145(3) 
0 8593(2) 
0 1196(3) 
0 7389(2) 
0 2442(3) 
0 8156(2) 
0 25 
0 51(9) 
0 51(9) 
0 51(9) 
0 49(9) 
0 49(9) 
0 49(9) 
0 33(9) 
0 33(9) 
0 33(9) 
0 67(9) 
0 67(9) 
0 67(9) 
0 137(6) 
0 0429 
0 0671 
0 08(1) 
0 0621 
0 0791 
0 0655 
0 0893 
0 0562 
0 0763 
0 0843 
0 0844 
0 0843 
0 0844 
0 0843 
0 0844 
0 0844 
0 0844 
0 0844 
0 0693 
0 0787 
0 0693 
0 0787 
0 0693 
0 0787 
0 0787 
0 0787 
0 0787 
0 0312 
0 0488 
0 0421 
0 0662 
0 0421 
0 0662 
0 0466 
0 0794 
0 0466 
0 0794 
0 0467 
0 0760 
0 0467 
0 0760 
0 0412 
0 0623 
0 0412 
0 0623 
0 0404 
0 0643 
0 0404 
0 0643 
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H161 
H162 
H171 
H172 
H173 
H181 
H182 
H183 
1 0675(6) 
0 5258(4) 
1 0278(6) 
0 5064(4) 
1 2841(5) 
0 2871(5) 
-1 2782(5) 
0 2673(5) 
-1 2385(5) 
_ 
0 1304(6) 
-
0 2614(6) 
-
0 2812(6) 
0 1612(7) 
-0 1613(4) 
0 1697(7) 
-0 1829(4) 
0 1866(8) 
-0 0923(5) 
-0 0233(8) 
-0 0805(5) 
-0 0149(8) 
-0 2421(5) 
-0 2905(5) 
-О 3023(5) 
-0 1134(4) 
0 7255(3) 
0 2403(4) 
0 8023(3) 
-0 2356(4) 
0 6910(3) 
-0 1698(4) 
0 7684(3) 
-0 2968(4) 
0 7147(3) 
0 7767(3) 
0 6994(3) 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
0 0486 
0 0826 
0 0486 
0 0826 
0 0660 
0 0999 
0 0660 
0 0999 
0 0660 
0 1189 
0 1189 
0.1189 
Discussion of the x-ray structures 
Plots of the numbering schemes used for both ropivacaine (i) and bupivacaine (2) are 
shown in fìg.3.4. Selected bond lengths, valence angles and torsion angles, obtained 
using PARST (Nardelli 1983), are tabulated in tables 3.3, 3.4 and 3.5. Table 3.6 lists the 
geometry of the disordered ethanol in (2) bupivacaine. No anomalous geometric 
values are observed. A geometric feature of interest of both local anesthetics is the mo-
lecular conformation as compared to, for example, the closely related lidocaine de-
rivatives (fig.3.5). The related compounds were found using a connectivity search on 
the Cambridge Crystallographic Database (CSD) (Allen 1979) using 2,6-acetoxylid-
ide as search fragment. This search gave 7 structures with 9 unique fragments. In the 
CSD use is made of so called reference codes to identify entries. The 7 structures 
found are designated BEFLUT (Faggiani 1982), BEVMOE (glowka 1981), 
LIDCAN10 (Hanson 1974), LIDNPP (Yoo 1975), LIDOCA10 (Hanson 1972), 
LIDOCN (Hanson 1972) and LIPFAZ (Germain 1977). The fragments are charac-
terized by 2 planar groups: the 'phenyl-group' consisting of the atoms Ci to C8 and 
Ni, and the 'amide-group' consisting of the atoms Ci, Ni, C9, Oi, d o (averaged de-
viations from l.s. planes in the retrieved entries vary from 0.002 to 0.034A). In table 
3.7 the angles between the phenyl groups and amide groups are given. Also, extending 
the comparison of lidocaine derivatives by Yoo et al (1975) in table 3.7, the conforma-
tion along the main chain (i.e. C1-N1-C9-C10-N2) is given, together with relevant 
crystallographic characteristics of the structures extracted from the CSD. 
In order to compare these structures correctly, it was necessary to generate sym-
metry releated (inverted) fragments for bupivacaine, BEFLUT, one of the unique 
fragments of BEVMOE and LIDOCA10. Inclusion of the conformation along the 
main chain for LIPFAZ is questionable since it's spacegroup symmetry prohibits in-
version. The conformation along the main chain of the inverted structure of LIPFAZ 
was added to table 3.7 because the resemblcnce of this conformation with the confor-
mation of ropivacaine is striking. 
38 
;A 
Figure β.4-' Perspective drawings of ropivacaine (upper) and bupivacaine (under). 
39 
Table 3.3:Bond lenghts (Ä) for non-Η atoms of (1) ropivacaine and (2) bupivacaine. 
(1) Ropivacaine (2) Bupivacaine 
C1-C2 
C1-C6 
C1-N1 
C2-C3 
C2-C7 
C3-C4 
C4-C5 
C5-C6 
C6-C8 
C9-C10 
C9-01 
N1-C9 
N2-C15 
C10-C11 
C10-N2 
C11-C12 
C12-C13 
C13-C14 
C14-N2 
C15-C16 
C16-C17 
C17-C18 
1 395(4) 
1.395(4) 
1.416(4) 
1.395(2) 
1.529(6) 
1.395(4) 
1.395(4) 
1.395(2) 
1.524(6) 
1.538(5) 
1.230(5) 
1.323(5) 
1.520(5) 
1 527(5) 
1 499(5) 
1 533(6) 
1 511(6) 
1 511(6) 
1.513(5) 
1 495(7) 
1.517(7) 
1.394(4) 
1.395(4) 
1.409(4) 
1.395(3) 
1.498(5) 
1.395(4) 
1 395(4) 
1.395(3) 
1 503(6) 
1.521(5) 
1 243(4) 
1.324(5) 
1.503(5) 
1.531(5) 
1.491(5) 
1.516(6) 
1.494(7) 
1.513(6) 
1.500(5) 
1.495(5) 
1.515(6) 
1.477(7) 
CH, 
CHj О N+-
CH, 
О N + - ^ 
CH, 
Figure }.$: Schematic drawings of ropivacaine (A) and lidocaine (B) active forms. 
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Table 3 5 Torsion angles (0) for non-hydrogen atoms for (1) ropivacaine and (2) bupivacaine 
(1) Ropivacaine (2) Bupivacaine 
C1-C2-C3 C4 
C I N I C9-C10 
C1-N1-C9-01 
СЮ СП C12-C13 
C10-N2-C15-C16 
СП C10N2C14 
C11-C10-N2-C15 
C11-C12C13-C14 
C12-C13-C14-N2 
C13-C14-N2-C10 
C13-C14-N2-C15 
C14-N2-C15-C16 
C15-C16-C17-C18 
C2-C1-C6 C5 
C2-C1 C6-C8 
C2-C1-N1 C9 
C2-C3-C4 C5 
C3-C4 C5 C6 
C4-C5-C6-C1 
C4-C5-C6-C8 
C6 CI C2-C3 
C6-C1-C2 C7 
C6-C1-N1-C9 
C7-C2-C3-C4 
C9-C10-C11-C12 
C9-C10-N2-C14 
C9C10N2-C15 
N1-C1-C2-C3 
N1 CI C2 C7 
N1-C1-C6-C5 
N1 CI C6C8 
N1-C9-C10-C11 
N1 C9C10-N2 
N2-C10-C11-C12 
N2-C15-C16-C17 
O1-C9-C10-C11 
O1-C9-C10-N2 
-0 0(4) 
177 8(3) 
0 2(6) 
56 3(5) 
-57 5(5) 
61 9(4) 
-172 3(3) 
-55 5(5) 
57 9(4) 
-60 7(4) 
170 9(3) 
67 4(5) 
01(4) 
-178 2(3) 
-103 1(4) 
0 0(4) 
0 0(4) 
-0 0(4) 
178 2(3) 
-0 0(4) 
-177 9(4) 
79 4(5) 
177 9(4) 
179 5(3) 
-178 5(3) 
-52 7(4) 
-177 5(3) 
4 6(5) 
177 6(3) 
-0 7(5) 
-97 3(4) 
142 9(3) 
-60 1(4) 
-177 0(4) 
80 3(5) 
-39 5(5) 
0 0(4 
-170 1(3 
5 6(6 
-55 2(5 
66 8(4 
-55 6(4 
175 9(3 
56 6(5 
-58 2(5 
57 9(4 
-172 8(3 
-61 5(4 
-167 0(4 
0 1(4 
-180 0(3 
104 3(4 
0 0(4 
0 0(4 
-0 0(4 
-180 0(3 
-0 1(4 
178 9(3 
77 4(4 
-179 0(3 
172 8(3 
-173 2(3 
58 3(4 
178 2(3 
-2 8(4 
-178 2(2 
18(4 
98 1(4 
-143 0(3 
54 6(4 
-179 9(4 
-77 8(4 
41 1(4 
Table 3 6 Geometry of the disordered ethanol in (2) bupivacaine (Symmetry code. ' 1-x,-y,2-z) 
С19-020 
C19-021 
C19-C19' 
O20-C19-O21 
O20-C19-C19' 
021 C19 C19' 
1 401(18)À 
1359(21) À 
1 477(10) Â 
122 3(11)° 
106 2(9) ° 
125 0(10)° 
4 * 
Table 3 7 Conformational comparison of (1) Ropvacaine and (2) Bupivacaine w i t h selected related 
compounds 
Name* 
(DRopi* 
(2)Bupi* 
BEFLUT 
BEVMOE1* 
LIDOCA10* 
Space 
Р2Г 
P21/n 
P21/C 
Р21/С 
C2/C 
LIPFAZ P212121 
LIDNPP* 
LIDOCN 
LIDCAN101 
LIDCAN102 
BEVMOE2* 
P21/C 
P2Vc 
P21/C 
P21/C 
P21/C 
R 
0 056 
0 064 
0 043 
0114 
0 044 
0 090 
0 067 
0 110 
0110 
0110 
0114 
angle1 
78 4 
71 9 
82 6 
888 
65 5 
71 4 
62 4 
71 9 
76 3 
82 1 
80 8 
$) For references of structures see text 
*) Protonated at N2 
*) Absolute configuration known 
' l Angle (°) between I s plane through CI to C8 and N1 and I s plane through CI, N1,C9, 01 and C10 
2) Torsion angles Tij {") accord ing t o Klyne and Prelog (Klyne 1960) 
T11=C2-C1-N1 C9 T12=C6-C1-N1-C9 T21=C1-N1-C9 0 1 
T22=C1-N1-C9-C10 T31=N1-C9-C10 N2 T32=O1-C9-C10-N2 
T41=C9-C10-N2 C14 T42=C9-C10 N2 C15 
3) Intramolecular h y d r o g e n b o n d b e t w e e n 
1 N2-H 0 1 
2 N1-H N2 
- none 
From this comparison it is very likely that the structure of LIPFAZ as published by 
Germain et al. (1977) should be inverted. Yoo et al. (1975) compared the conforma­
tions of the main chain of LIDNPP, LIDOCN and LIDOCA10, and reported a 
different conformation for LIDOCA10 compared to LIDNPP and LIDOCN. 
Ropivacaine and bupivacaine resemble the conformation of LIDOCA10. Also, from 
the structures extracted from the CSD, the conformations of the main chain of 
BEFLUT, of one of the independent molecules of BEVMOE and of LIPFAZ can be 
regarded as belonging to the same group. A totally different conformation is found 
for both molecules in LIDCAN10, where the intramolecular N1-H...N2 hydrogen 
bond dominates the conformation of the main chain. 
The conformation of the main chain of the other independent moiety in 
BEVMOE is different from all of the other conformations found. It should be noted 
that intermolecular hydrogen bonds play a role in the conformation of the main 
chain. For the conformations listed in table 3.7, all nitrogen atoms N1 act as intermo­
lecular hydrogen bond donors, as do the protonated nitrogen atoms N2. For the en­
tries in which the nitrogen atoms N2 are not protonated (BEFLUT, LIPFAZ, 
LIDOCN and LIDCAN10), N2 atoms do not take part in intermolecular hydrogen 
bonding as acceptors. For the amide oxygen atoms Oí, intermolecular hydrogen 
T11' 
103 1 
104 3 
-98 6 
-89 4 
111 1 
-73 5 
1136 
105 6 
-80 7 
-82 4 
1010 
T12 
79 4 
77 4 
82 3 
93 4 
70 1 
106 9 
67 9 
76 9 
102 9 
98 3 
79 0 
T21 
02 
-5 6 
07 
04 
-5 6 
44 
62 
-4 9 
51 
00 
35 
T22 
177 8 
170 1 
-179 8 
177 8 
173 3 
-179 2 
172 2 
173 8 
-177 1 
-179 4 
-177 7 
T31 
142 9 
143 0 
157 0 
143 6 
168 0 
1419 
149 7 
1315 
52 
18 
168 8 
T32 
39 5 
-41 1 
-23 5 
-39 0 
-13 0 
-41 9 
-31 8 
-49 8 
-177 0 
178 8 
-12 4 
T41 
-178 5 
173 2 
168 6 
168 1 
153 4 
170 0 
79 0 
72 9 
-128 8 
-131 1 
-123 5 
T42 
-52 7 
-58 3 
-68 3 
63 9 
-78 1 
66 1 
-50 4 
57 0 
107 0 
1159 
1185 
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bonds are found for the entries BEVMOE (for only one independent molecule), 
LIDOCAio, LIDOCN and both independent molecules of LIDCANio, and ropiv-
acainc. 
Although the conformations of the ropivacaine and bupivacaine cations arc very 
similar (for a l.s. fit of all common non-hydrogen atoms, fìg.3.6; mean deviation = 
0.22A), the molecular packing arrangements are quite different. In (1) ropivacaine, 
adjacent ropivacaine cations are joined by strong hydrogen bonds to water, i.e. be-
tween O1...H-O2 and Ο2...ΗΓ-Ν1', to form chains parallel to b. Also, the anionic 
chlorine participates in the hydrogen bonding by accepting a waterproton and an 
amino-proton. The amino-proton could not be located, but distances and angles in­
volved in the assumed hydrogen bonding scheme are acceptable. The rather weak 
intramolecular hydrogen bond benveen Oi and N2 as described by Hanson (1972) is 
less favourable than the N2...C11 hydrogen bond. 
Table 3.8 summarizes the distances and angles involved in hydrogen bonding. Fig. 
3.7 shows the packing along the a-axis for (1) ropivacaine. Fig.3.8 shows a perspective 
drawing of the crystal packing along the a-axis for (2) bupivacaine. 
1 1 
Figure j.6: Stick drawing of the ropivacaine and bupivacaine cations (non-hydrogen atoms only) 
showing their similar overall conformation. Solid lines ropivacaine; dashed lines bupivacaine. 
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Figure¡.j: Hydrogen bonded chains in (i) ropivacaine, viewed perpendicular to b, c,-planc. 
45 
«so 
«во 
Figure}.8: Hydrogen bonded chains in (2) bupivacaine, viewed perpendicular to b, c-plane. 
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Table 3.8: Distances (À) and angles ("I involved in hydrogen bonding for (1) ropivacaine. 
CL1...N2 
CL1...02 
01...N2 
01...02 
N1...02a 
HI...02a 
N1-H1...02a 
Symmetry Code 
None: x.y.z; 
a: x,y+1,z 
3.107(3) 
3.109(4) 
2.836(4) 
2.838(4) 
2 910(5) 
2.09(5) 
175(4) 
Table 3.9: Distances (Á) and angles (°) involved In hydrogen bonding for (2) bupivacaine. 
CL1...N1 
CL1...H1 
N1-H1...CL1 
01...N2 
01...H2 
N2-H2...01 
CL1...N2a 
CLl...H2a 
N2a-H2a...CL1 
CL1...O20a 
CL1...021b 
Symmetry code 
None. x,y,z ; 
a:-x+3/2,y-1/2,-z+3/2; 
b:x+1/2,-y-1/2,z-1/2 
3.183(3) 
2.35(4) 
173(4) 
2 771(4) 
2.58(4) 
94(4) 
3.100(3) 
2.32(4) 
156(4) 
3.321(17) 
3.291(19) 
Bupivacaine cations, chlorine anions and the disordered ethanol molecules are held 
together by hydrogen bonds and van der Waals contacts to form layers parallel to the 
plane characterized by the 'Miller indices' ιοί. All positions of the disordered ethanol 
are shown to illustrate the connection in the total hydrogen bonding scheme. As in (i) 
ropivacaine, the hydrogen bond between Cli and N2 is stronger than the intramo­
lecular hydrogen bond between Oi and 2, because of the unfavourable angles in­
volved in the latter. Table 3.9 summarizes the hydrogen bonding scheme in terms of 
distances and angles. The layers perpendicular to the 'Miller plane' 101 show a non-
polar interaction between the inversion related adjacent phenyl rings of the bupiv­
acaine cations (Fig. 3.8). The distance between the least-squares planes through the 
adjacent phenyl rings is only 3.08Â. Adjacent layers are held together by van der 
Waals contacts. 
Ropivacaine and bupivacaine crystallize in the same conformation, although their 
crystallographic packing schemes are quite different. This conformation of active 
(protonated) form of both molecules was recognized earlier in related lidocaine de-
rivatives. 
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CHAPTER 4 
CardiovascuUr effects of epidural blockade 

Introduction 
Corning has been credited with being the first to use epidural analgesia in 1885 
(Corning 1885). Epidural analgesia has been practiced since 1901 with the use of sever-
al techniques. Sicard and Cathelin popularized the caudal approuch. In 1921 Fidel 
Pages renewed interest in the midline lumbar approach (Pages 1921). The introduc-
tion of the Tuohy's needle and the epidural catheter, managed to escape the genera 
decline in use of regional techniques (Fink 1988). 
During the 1960s, epidural blockade became the most widely used technique of 
neural blockade for postoperative and obstetric pain relief. The development of long-
acting local anesthetics and increasing knowledge of the physiology of regional anes-
thesia have ensured that epidural anesthesia is safe and practical. 
However, the administration of local anesthetic drugs into the epidural space af-
fects the cardiovascular system in a number of ways. The cardiovascular effects asso-
ciated with epidural blockade arc related to: 
1 The type and dosage of the local anesthetic agent. 
2 The addition of vasoconstrictors. 
3 The level of sympathetic blockades. 
4 The blood volume status of the patient. 
Toxicity of local anesthetic agents 
Local anesthetic agents are relatively free from side effects if they are administered in 
an appropriate dosage and in the appropriate anatomical location. However, systemic 
and localized toxic reactions may occur. 
Local anesthetics when employed clinically, rarely produce localized nerve dam-
age. In recent years, prolonged sensory deficits have been reported in some patients 
following the normal extradural or intrathecal administration of large doses of chlo-
roprocaine (Reisner 1980). The cause of the potential neurotoxicity is believed to be 
related to the low pH and the presence of sodium bisulphite, an antioxidant. Skeletal 
muscle appears to be more sensitive to the local irritant properties of local anesthetic 
agents than other tissues. In general, the more potent and longer acting agents cause a 
higher degree of damage than the less potent and shorter acting agents. This effect on 
skeletal tissue is reversible and regeneration occurs within 2 weeks. 
Systemic reactions to local anesthetics primarily involve the central nervous and 
the cardiovascular systems. These reactions are due to the inappropriate use of local 
anesthetics, such as accidental intravascular or intrathecal administrations of an exces-
sive dosage. 
In general the central nervous system is more susceptible to local anesthetics than 
the cardiovascular system (Scott 1981). The most common manifestation of central 
Ji 
nervous system toxicity is related to central nervous excitation (dizziness, tinnitus and 
convulsions). This central nervous excitation also results in cardiovascular changes: 
hypertension, tachycardia and dysrhythmias (Heavner 1986). 
Considerable interest in cardiotoxicity of local anesthetics has developed over the 
last decade. This interest stemmed from cardiac deaths induced by bupivacaine and 
etidocaine (Albright 1979). Direct local anesthetic induced cardiovascular depressions 
occur less frequently than central nervous system reactions. However, adverse effects 
involving the cardiovascular system tend to be more serious and more difficult to 
manage. Administered local anesthetics can exert a direct action both on cardiac 
muscle and on vascular smooth muscle. 
Cardiac effects: cardiodepression and cardiac dysrhythmias 
The mechanism of direct cardiac depression by local anesthetics involves effects of 
ionic conductance in myocardial conducting membranes and in the myocardial con-
ducting system. A decrease in maximum rate of depolarization is believed to be due to 
an interaction with the fast sodium channels in the cardiac membrane, which results 
in a decreased rate of depolarization(CIarkson 1985). The ability of local anesthetic 
drugs to depress the contractility of cardiac muscle is proportional to their ablility of 
cardiac muscle to suppress conduction in peripheral nerves. 
However, death following administration of local anesthetics is due to severe car-
diac dysrhythmias: ventricular arrhythmias and ventricular fibrillation (Kotelko 
1984). The electrophysiological changes produced by bupivacaine suggest that re-
entry phenomena may cause severe ventricular arrhythmias (Moller 1988). Several 
studies have been performed to compare the electrophysiological effects of ropiv-
acaine and bupivacaine. In all these studies ropivacaine appears to provide a greater 
margin of safety than bupivacaine (Pedigo 1988, Nancorrow 1989, Reiz 1989, Moller 
1990). 
Vascular effects 
Local anesthetic agents can exert significant effects on peripheral blood vessels. 
Studies have demonstrated that local anesthetic agents have a biphasic action on 
smooth muscle of peripheral blood vessels (Blair 1975). Low concentrations of local 
anesthetics causes an increase in basal tone of the vascular smooth muscle. By increas-
ing the dose of the local anesthetic agent, the stimulatory or vasoconstrictor action 
changes to inhibition and vasodilatation. All of the local anesthetic agents which have 
been studied exert this biphasic effect with the exception of cocaine and ropivacaine. 
In a comparative study with bupivacaine, ropivacaine appeared to be an effective 
vasoconstrictor for the cutaneous microvasculature (Kopacz 1988). Dahl et al (1990) 
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demonstrated that epidural blood flow decreased 37% after administration of ropiv-
acaine, compared to a 17% increase with bupivacaine. 
Vasoconstrictors 
Vasoconstrictors are frequently added to local anesthetic solutions to reduce toxicity, 
prolong duration and improve the intensity of blockade. Local anesthetic solutions 
usually contain a 1:200.000 (5 lig.ml·1) concentration of epinephrine. Vasoconstric-
tors are less effective in prolonging the anesthetic properties of long acting drugs 
(Covino 1976). In extradural blockade duration of adequate analgesia was only im-
proved when epinephrine 1:200.000 was added to 0.125% ^ d 0.25% bupivacaine. 
The value of adding epinephrine to long acting drugs is the reduction of the potential 
danger of systemic toxic local anesthetic reactions, by a reduction of peak plasma con-
centrations (Burm 1985). However, the addition of epinephrine to local anesthetics 
also exerts systemic circulatory effects by stimulating both alpha and beta adrenergic 
receptors. Bonica and associates describe the effects of epinephrine (Bonica 
1971).Chapter 6 of this thesis describes the effects of 100 |Jg epinephrine added to 20 
ml 0.5% bupivacaine used in epidural blockade. 
Sympathetic blockade in epidural blockade 
Epidural blockade results in sympathetic nerve block. The cardiovascular effects de-
pends on the site and level of the block. Lumbar epidural blockade up to T5 causes ar-
teriolar and venous dilatation in the pelvis and lower limbs. This results in a decrease 
in venous return and consequently a reduced cardiac output. Blockade above T5 af-
fects not only sympathetic vasoconstrictor fibres but also the sympathetic innervation 
of the heart. This results in a reduction in heart rate and cardiac output. The reduc-
tion in cardiac output is related to the inhibition of myocardial sympathetic fibres re-
sulting in a decreased cardiac contractility and also in a decrease in venous return 
from venodilatation and expansion of capacitance vessels (Ward 1965). The effects of 
sympathetic blockade may be exaggerated in certain cardiac conditions. However, 
Baron showed that decrease in left ventricular loading induced by lumbar epidural 
anesthesia may improve left ventricular function in patients with stable mild related 
angina (Baron 1987). 
Blood volume status of the patient 
Cardiovascular changes are more pronounced in hypovolemic patients (Bonica 1972). 
Epidural anesthesia in hypovolemic volunteers is associated with profound hypoten-
Î3 
sion. The addition of epinephrine to the local anesthetic solution usually results in a 
less profound hypotension. 
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CHAPTER 5 
Noninvasive hemodynamic monitoring by thoracic bioimpedani 
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Introduction 
Blood transports oxygen and nutrients to the tissues and removes waste products 
from the tissues that have been produced in metabolic processes. The circulatory sys-
tem consists of three main components: the heart, the blood vessels and the blood. 
The heart provides the pumping force necessary to circulate the blood throughout 
the bloodvessels. As the body's need for oxygen and nutrients alters, tissue perfusion 
changes through central and local modulation, i.e. vasoconstriction-vasodilatation 
and change in cardiac output. 
Cardiac output is defined as the volume of blood ejected by the heart per unit of 
time (minute). Cardiac output is the product of heart rate and stroke volume. 
Cardiac output measurements are used to monitor cardiovascular performance and to 
assess the response of patients to drugs. 
The stroke volume is the volume of blood ejected by the heart during each con-
traction. Over a period of time cardiac output must equal venous return. Under nor-
mal circumstances the major factor determining the stroke volume is the rate of ve-
nous return (Guyton 1959). The intrinsic ability of the heart to adapt to changing ve-
nous return is described by Frank and Starling (1895). Basically, the Frank-Starling 
law states that the force of cardiac contraction increases in proportion to the degree of 
diastolic stretch (preload) of the myocardial fiber (Noble 1978). 
Preload is defined as the initial ventricular muscle fiber length at end-diastole. 
Clinically, preload is determined by the ventricular end-diastolic volume. Changes in 
left ventricular end-diastolic volume will alter left ventricular end-diastolic pressure, 
which is reflected by the pulmonary capillary wedge pressure (Swan 1970). 
Ejection fraction, defined as the ratio of stroke volume to end diastolic volume, is 
a global index of the extent of ventricular fiber shortening. The ejection fraction has 
the advantage of being dimensionless; therefore, it does not require correction for 
body size. 
Cardiac output measurements 
'Foday, numerous methods are available for the measurement of cardiac output. One 
way to categorize the methods of cardiac output is based on their invasiveness (Ehlers 
1986). The majority of techniques are invasive, requiring entrance into the body (di-
lution technique, electromagnetic flow probe and Fick). This increases the risk of in-
fection, thrombosis, vessel perforation and air embolism (Shah 1984). Several tech-
niques exist which allow cardiac output measurement without entering the body; 
hence, they are classified as noninvasive. Transthoracic bioimpedance and doppler ul-
trasound methods are two noninvasive techniques presently used. 
The ideal method would be noninvasive, continuously, easy to perform, safe and 
inexpensive. In the discussion of any technique two characteristics must be consid-
ered: accuracy and reproducibility. 
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Monitoring of cardiovascular effects in epidural blockade 
Administration of local anesthetics influences the cardiovascular system leading to 
hemodynamic alteration. Monitoring of patients during regional anesthesia is done 
to determine the change in the hemodynamics and to evaluate the response to admin­
istered vasoactive drugs. 
The indications for cardiovascular monitoring in patients undergoing epidural 
anesthesia are: 
ι Measurements of quantitative alterations in cardiovascular functions (blood pres­
sure, heart rate, cardiac output). 
2 Monitoring of changes in hemodynamics during surgery caused by blood loss and 
body position. 
3 Evaluation of cardiovascular function after administration of new local anesthet­
ics. 
4 Evaluation of the treatment of the hemodynamic changes (bradycardia, hypoten­
sion), which often involves administration of potent drugs with specific cardiovas­
cular cflfects. 
The effects of epidural blockade on physiologic parameters have been discussed in 
chapter 4. In general, cardiovascular depression is related to the level of the sym­
pathetic blockade, the dose and the cardiotoxicity of the administered drug. 
The minimal standards for basic peri-operative monitoring are continuous ECG 
tracing, plethysmography and arterial blood pressure measurement (Gezondheidsraad 
1978). When cardiovascular parameters are measured, the intervention-related risk to 
the patient must always be carefully balanced against potential benefit. Hence the use 
of non-invasive methods are most desired. 
Thoracic bioimpedance monitoring 
When a high frequency alternating current is applied across the chest, changes in the 
thoracic impedance can be recorded. In the early decades of this century many 
authors used this principle to study the volume changes of the heart. The method 
used for calculating stroke volume is based on spontaneous rhythmic variation in 
thoracic electrical bioimpedance. Such variation is induced by fluctuations in the cali­
ber of the large vessels, which in turn are caused by the cardiac cycle. For this reason 
the method was called impedance plethysmography (Nijboer 1950). 
In 1966, Kubicek developed a noninvasive method to estimate the cardiac output 
by thoracic bioimpedance, yielding acceptable correlation with invasive methods but 
reliable only in healthy men (Kubicek 1966). The empirically derived formula to cal­
culate stroke volume is: 
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L2 
τ ( d Z / d t U . T (5.1) 
_ 2 
stroke volume, ml 
specific resistivity of blood, ohm.cm"1 
length of measured segment, cm 
basic impedance, ohm 
ventricular ejection time, seconds 
the maximum inflection of the first derivative (dZ/dt) 
of impedance changes, ohms.s"1 
In several studies the method of measuring cardiac output by Kubicek's impedance 
equation , when compared with other techniques (thermodilution, Pick, radionuclide 
angiocardiography), showed a good correlation (Kubicek 1966, Muzi 1985, Williams 
1985, Hatcher 1986). However, at that time expansion of the technology to patients 
with severe illnesses produced poor correlations. 
One of the major problems in equation 5.1 is the measurement of τ (resistivity of 
blood). Other limitations in the equation are: it assumes the thorax to be a cylinder, it 
overestimates stroke volume in wet-lung patients and it requires a period of apnea. 
The problems and deficiencies of the Kubicek equation were reevaluated by 
Sramek and Bernstein (Bernstein 1986). They proposed a new set of equations to ob­
viate the false assumptions of the Kubicek equation. The Sramek-Bernstein equation 
has since then been incorporated into the software of a microprocessor (the 
NCCOM-3, BoMed Medical Manufacturing, Ltd, Irvine, CA). The bioimpedance 
cardiac output monitor NCCOM-3 calculates stroke volume for every heart rate ac­
cording to equation 5.2. 
Figure 5.1 shows the time relationships between the electrocardiogram, arterial 
pressure, and dZ/dt waveform. The thoracic bioimpedance change is an approximate 
image of arterial pressure (middle curve in figure 5.1). The change in thoracic bioim­
pedance originates in two pressure related phenomena: the volumetric change in 
blood in the thoracic segment due to arterial pressure compliance and the alignment 
of red cells due to variation in velocity. By magnitude, the cardiovascular impedance 
change is approximately 0.5% of base impedance or 10% of ventilation impedance 
change. 
SV = 
SV 
τ 
L 
Zo 
Τ 
dZ/dt
m !,Y 
EVI 
SV = V E P T x V E T x (5-2) 
TEI 
SV = stroke volume, ml 
VEPT = physical volume of electrical participating thoracic tissue, ml 
L1 
VEPT =- — L = 17% of the patients height (cm) 
4.25 
VET = ventricular ejection time, seconds 
EVI = (dZ/dt)
m a x
 = ejection velocity index ohms.sec"1 
TEI = ZQ = thoracic fluid index, an indication of thorax fluid content, ohm 
ECG 
Δ Ρ or Δ Ζ 
dZ/dt 
Figure 51 Simultaneously recorded electrocardiogram (FCG), change in arterial pressure (ΔΡ) or change 
in cardiovascular impedance change (ΔΖ), and the first derivative of the thoracic impedance dZ/dt syst= 
systole, diast= diastole, PEP= pre-ejection period, VhT= ventricular ejection time, MC= mitral valve 
closed, AO= aortic valve open, AC= aortic valve closed, MO= mitral valve open 
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The TFI (thoracic fluid index) measured in ohms represents the total resistance of the 
thorax to the flow of electric current (2.5 mA., 70KH7.). Thus the TFI represents the 
contribution of the interstitial and intravascular fluids. The VET (ventricular ejection 
time) is the period in seconds of mechanical systole, measured between the opening 
and closure of the aortic valve in seconds. The EVI (ejection velocity index) is the 
maximum value measured in ohms of the rate of thoracic impedance change 
(dZ/dt)max. The VEPT (volume of electrical participating tissue) is the volume in ml 
of the truncated cone. 
The Sramek-Bernstein equation differs from equation 5.1 in that: 
1 The thoracic volume conductor is modelled geometrically as a truncated cone 
rather than as a cylinder. 
2 The specific resistivity of blood, X, is eliminated. 
3 The measured thoracic length is replaced in the equation by a volume of electrical-
ly participating tissue, calculated by the microprocessor (in the monitor) from the 
patient's height. 
Recent studies allow the comparison of cardiac output measurements by thoracic 
bioimpedance with several other methods, both in the clinical setting and in experi-
mental models. In the interpretation and discussion of the clinical results in com-
parisons between the thoracic bioimpedance method and other methods of cardiac 
output monitoring, we have to keep in mind that no perfect method for measuring 
cardiac output is available. Most of the studies confirm experimental and clinical 
findings with acceptable levels of correlation between thermodilution and thoracic 
bioimpedance cardiac output measurements (Hetherington 1985, Appel 1986, 
Bernstein 1986, Tremper 1986, Kerkkamp 1988). 
Based on changes in the electrical conductivity of the thorax, the NCCOM-3 has 
the capacity to display several cardiodynamic parameters. The standard, clinically 
used parameters are: heart rate, stroke volume, cardiac output, end diastolic volume 
and ejection fraction. As this technique is continuous and noninvasive, there is no 
harm to the patient. Therefore bioimpedance cardiac output monitoring has particu-
lar relevance in research concerning the hemodynamic effects of anesthetic agents or 
certain procedures which are known to cause cardiovascular disturbance. 
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CHAPTER 6 
Hemodynamic monitoring in epidural blockade: cardiovascular 
effects of 20 ml 0.5% bupivacaine with and without epinephrine 
HEM. Kerkkamp, M.J.M. Gielen 
This chapter has been published in Regional Anesthesia 1990:15:137-141. 
Parts of this study have been presented at the 14th Annual ASRA Meeting, Boston, USA, 
March 30-April 2,1989. 
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Abstract 
Twenty patients scheduled for elective urologie surgery received epidural anesthesia 
with 20 ml 0.5% bupivacaine. Ten patients received an epinephrine-free solution and 
ten patients received epinephrine 5 (Jg.ml"' added to the local anesthetic solution. The 
mean maximum level of sensory blockade was not different between the two groups 
(T7 and T8). After epidural administration of 20 ml of either solution, the mean arte-
rial blood pressure decreased significantly from pre-blockade values. After adminis-
tration of 0.5% bupivacaine with epinephrine, cardiac output, stroke volume and end 
diastolic volume increased significantly from pre-blockade control values. These 
changes occurred within two to four minutes after injection of the local anesthetic so-
lution and are caused by the systemic effects of epinephrine. After 15 minutes the ejec-
tion fraction in the plain bupivacaine group decreased significantly from pre-blocka-
de control values and the bupivacaine with epinephrine group. The differences in 
hemodynamic effects of the two solutions can be explained by the vasoactive effects of 
epinephrine and the cardiodepressive effects of bupivacaine. 
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Introduction 
The hemodynamic effects of epidural anesthesia are complex and are related to (i) the 
level of anesthesia, (2) the amount and type of anesthetic injected, (3) the addition of 
vasoconstrictors to the local anesthetic solution and (4) the physical status of the pa-
tient. Epidural blockade that is restricted to the level of the lumbar region results in 
peripheral sympathetic blockade with level vascular dilatation in the pelvis and lower 
limbs. If all splanchnic fibers are blocked (T6-L1), pooling of blood in the abdominal 
region may also occur. The blockade results in an arteriolar vasodilatation (decreased 
systemic vascular resistance) and pooling of blood in the venous capacitance vessels 
(Bonica 1971). Because the capacitance vessels contain 80% of the blood volume, ve-
nodilatation can have a dramatic effect on end diastolic volume, cardiac output and 
blood pressure. 
Low doses of local anesthetics decrease peripheral arterial flow without any change 
in systemic arterial pressure. Higher doses result in an increased blood flow in periph-
eral arteries indicating a state of vasodilatation. 
Since Braun first described the addition of epinephrine to local anesthetics, its 
pharmacokinetic and pharmacodynamic have been studied widely (Tucker 1975). 
The advantages of adding epinephrine to local anesthetics are the generation of a 
more intense block, a longer duration of anesthesia, and a reduction of systemic toxic 
reactions by reducing the peak plasma concentration (Stanton-Hicks 1973, Tucker 
1979, Burm 1986). 
In previous studies, the circulatory effects of epidural blockade with lidocaine-
epinephrine solutions were studied (Bonica 1971, Stanton-Hicks 1973). Cardiac out-
put was measured with invasive methods: thermodilution or dye dilution techniques. 
These techniques are expensive, can only be performed intermittently and are not 
without risk (Foote 1974, Barash 1981, Shah i984).Bioimpedance cardiac output 
monitoring has the advantage of being noninvasive and continuous. The continuous 
nature of the measurements is of great value for detection of changes in circulatory 
performance (Appel 1986, Hanna 1988, Mcmcnemin 1988). The aim of the present 
study was to measure heart rate, mean arterial blood pressure, stroke volume, cardiac 
output, end diastolic volume and ejection fraction in response to the lumbar epidural 
injection of 20 ml 0.5% bupivacaine in contrast to the injection of 20 ml 0.5% bupiv-
acaine with epinephrine 5 pg.ml"'. 
Methods 
Twenty patients ASA 1 or 2 scheduled for urologie surgery under epidural anesthesia 
were studied. The study was randomized and performed in a double blind fashion. 
The patients were divided into two groups: Group 1 received 20 ml 0.5% bupiv-
acaine, group 2 received 20 ml 0.5% bupivacaine with epinephrine 5 (Jg.ml·1. 
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The study was approved by the local Ethical Committee of the Hospital. Each pa-
tient was informed about the purpose of the study and oral consent was obtained. 
None of the patients had a history of cardiovascular disease or received cardiovascular 
medication. Premedication consisted of io mg diazepam orally, 60-90 minutes before 
inserting the epidural catheter. Each patient received 500 ml of a balanced electrolyte 
solution (NaCl-Dextrose), which was administered prior to the epidural catheter in-
sertion. 
The epidural space was identified by the loss-of-resistance technique, the patient 
being in the lateral position, using an 18 gauge Tuohy needle in the 2-3 or 3-4 lumbar 
epidural interspace via a midline approach. An epidural catheter was inserted to a 
depth of 3 cm and the patient was turned supine. 
Before injecting the local anesthetic solution, a 15-minutes rest period was ob-
served. Systolic, diastolic and mean arterial blood pressure were measured at 1 minute 
interval with an automatic blood pressure monitor (EME Bristol Gardens, England). 
Cardiovascular measurements (heart rate, cardiac output, stroke volume, end dias-
tolic volume and ejection fraction) were continuously obtained with the NCCOM-3 
cardiodynamic monitor (Bomed Medical Manufacturing, Irvine, California). The 
cardiovascular parameters obtained five minutes before epidural injection were used 
as prc-blockade control values. 
In order to exclude spinal placement of the catheter, a test dose of 3 ml 0.5% 
bupivacaine or 3 ml 0.5% bupivacaine with epinephrine 5 mg.ml"1 was injected. 
Approximately three minutes after the test dose, the remaining 17 ml of one of the 
bupivacaine solutions was injected within one minute. The hemodynamic measure-
ments were continuously monitored started at the end of the bupivacaine injection 
(t=o), for 30 minutes, with the patient still in the supine position. Sensory analgesia 
was determinated by the pinprick method using a blunt 27-gauge needle. After 30 mi-
nutes, the patient was transported to the operating theatre and surgery was performed. 
The data are expressed as relative changes from the pre-blockade control values, 
taking the pre-blockade values as 0%. Statistical analyses between the control values 
and the changes in each group were performed using the Student's paired t-test. The 
significance of the difference between the means of the two solutions were calculated 
with the unpaired t-test. P< 0.01 was considered statistically significant. 
Results 
Twenty male patients participated in the study. There was no difference between the 
groups with regard to age, height and weight (table 6.1). 
Onset and spread of analgesia 
The dermatomal levels reached for the two groups are shown in figure 6.1. For the 
majority of patients in both groups, the upper analgesic limit reached T7. No signifi-
es 
cant differences in onset times were found between the two groups at any segmental 
level. 
Hemodynamic effects 
The absolute figures for the hemodynamic measurements (control values) before in­
jection of the local anesthetic drug are shown in table 6.2. In table 6.3 the relation be­
tween mean maximum relative hemodynamic changes from control values and time 
from the end of epidural injection is given. 
Table 6.1: Demographic data (mean + SEM). 
Bupivacame 0 5% 
(n=10) 
Age (years) 57(6.1) 
Weight (kg) 75(3 8) 
Height (cm) 174(2.6) 
Bupivacame 0.5% with epinephrine 5 цд.глі-1 
(n=10) 
61(4.8) 
73(2 7) 
173(1.8) 
n= number of patients 
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Figure 6.i: The onset of sensory blockade after epidural injection. Values are means + SEM. 
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Table 6 2 Mean pre-blockade hemodynamic values with standard deviations between parentheses (control 
value = 0% change). 
Bupivacaine 
Heart rate (bpm) 74(16) 
Mean arterial blood pressure (mm Hg) 100(17) 
Stroke volume (ml) 67(19) 
Cardiac output (l/mm) 5 0< 1 6) 
End diastolic volume (ml) 130(35) 
Ejection fraction (%) 57(10) 
Bupivacaine with epinephrine 
78(14) 
101(14) 
72(24) 
5 7(18) 
110(27) 
61(9) 
Table 6 3 Relation between mean maximum relative hemodynamic changes from control values and the 
time after the end of epidural injection 
HR 
MAP 
SV 
CO 
EDV 
EF 
chai ige(%) 
+5 
-17* 
-16 
-11 
+ 11 
- 1 2 " 
Bupivacaine 
time(minutes) 
20 
20 
25 
25 
15 
25 
Bupivacaine with epinephrine 
change(%) time(minutes) 
-6 2 
-11 * * 15 
+53* 10 
+60* 15 
+43* 10 
+5 10 
HR=heart rate, MAP=mean arterial pressure, SV=stroke volume, CO=cardiac output, EDV=end diastolic vol-
ume, EF=ejection fraction 
Significant change from control * p < 0 001, ** p < 0 01 
Changes in heart rate are illustrated in figure 6.2. The changes in heart rate within the 
groups were not significant, nor were the changes between the two groups. Mean ar-
terial blood pressure decreased significantly in both groups, five minutes after the end 
of injection (figure 6.3). No significant differences were found between the two 
groups with regard to changes in mean arterial blood pressure, although the plain 
bupivacaine group tended to decrease more. Significant hypotension (defined by 
>3o% drop in pre-blockade systolic blood pressure) requiring administration of intra-
venous drugs was not observed in this study. 
Changes in stroke volume and cardiac output arc illustrated in figures 6.4 and 6.5, 
respectively. Two minutes after injection of bupivacaine with epinephrine, stroke vol-
ume and cardiac output increased significantly from control values. Maximum mean 
relative change in stroke volume was 53%, ten minutes after the end of epidural injec-
tion of bupivacaine with epinephrine. Maximum mean relative change in cardiac out-
put was 60% and occurred 15 minutes after epidural injection. Significant differences 
in stroke volume and cardiac output between the two groups occurred after four and 
eight minutes respectively. The maximum relative change in end diastolic volume was 
43%, ten minutes after the end of the bupivacaine with epinephrine injection (figure 
6.6). 
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Figure 6 2 Changes in heart rate Each point represents the mean (± SEM) relative change from control 
values Г= -5 represents the mean pre-blockadc injection control value I =o represents the values at the 
end of the epidural injection 
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Figure 6i Changes in mean arterial blood pressure Each point represents the mean (± SFM) relative 
change from control values Statistical significant differences within the groups are indicated by * 
Comparison of the mean relative change in ejection fraction between the two groups 
showed a significant difference six minutes after the end of the epidural injection of 
the local anesthetics (figure 6.7). While no significant changes from control were ob­
served in the bupivacaine with epinephrine group, the ejection fraction for the plain 
bupivacaine group decreased significantly 15 minutes after injection. The maximum 
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relative change in ejection fraction was -12% in the plain bupivacaine group and oc­
curred 25 minutes after epidural injection. 
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Figure 64- Changes in stroke volume Each point represents the mean (± SEM) relative change from 
control values. Statistical significant differences within the groups are indicated by » and between the 
groups by О · 
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Figure 6$ · Changes in cardiac output. Each point represents the mean (± SEM) relative change from 
control values. Statistical significant differences within the groups are indicated by * and between the 
groups by О . 
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Figure 6 γ Changes in ejection fraction Each point represents the mean (± SEM) relative change from 
control values Statistical significant differences within the groups are indicated by * and between the 
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Discussion 
In 1971 Bonica et al. described the cardiovascular effects of epinephrine added to lido-
caine (Bonica 1971). In contrast to our results, they found a 10% decrease in mean ar-
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terial blood pressure in the lidocaine-epinephrine group and a 5% decrease in the 
plain group. Bonica et al. suggested a synergistic action between the resorption of 
epinephrine and vasomotor blockade. No significant differences in mean arterial 
blood pressure were found between the two groups in our study. In contrast to the 
observations of Bonica et al., we did not find an increase in heart rate. The maximum 
relative increase in cardiac output was 60% after 15 minutes in the bupivacaine-epi-
nephrine group. Bonica et al. found a 49% increase in cardiac output after 15 minutes. 
The major factor responsible for these changes is an increased stroke volume. Two 
minutes after injection of the bupivacaine with epinephrine solution, stroke volumes 
increased significantly from control and persisted more than 30 minutes. Changes in 
end diastolic volume (preload) contributed to the increased stroke volume. 
In 1958 Guyton et al. showed the effects of epinephrine on the venous return 
(Guyton 1958). They illustrated that by increasing the rate of intravenous epinephrine 
infusion under total spinal anesthesia, the venous return to the heart increased 
progressively with constant right atrium pressures. Guyton concluded that the rise in 
cardiac output caused by epinephrine is caused mainly by the increased venous return 
rather than the increased contractility of the heart. 
An experimental study in sheep by Ottesen et al., demonstrated that after the in-
duction of lumbar epidural analgesia with mepivacaine, the effect of intravenously in-
jected epinephrine was an increased venous return to the heart (Otteson 1978). In our 
study, the venous uptake of epinephrine from the epidural space resulted in a veno-
constriction followed by an increased end diastolic volume and stroke volume in the 
first minutes after epidural injection. 
Another interesting finding in our study was the decreased ejection fraction in the 
plain bupivacaine group. Fifteen minutes after epidural injection, the ejection frac-
tion decreased significantly in the plain bupivacaine group, with the maximum de-
crease after 25 minutes (-12%). In the bupivacaine with epinephrine group the ejec-
tion fraction did not change significantly. In previous studies, the cardiodepressive ef-
fects of bupivacaine were studied (Nath 1986). Beai et al. showed that a significant re-
duction in cardiac output already occurred with an intravenous bupivacaine infusion 
at a rate of 0.2 mg-kg^-min-1 (Beai 1988). 
Twenty minutes after epidural administration, a maximum bupivacaine plasma 
level was observed by Wilkinson and Lund (Wilkonson 1970). The decrease in ejec-
tion fraction that also occurred around that time in our study can be explained by the 
cardiodepressive effects of the absorbed bupivacaine. The epinephrine counteracts 
these effects in the bupivacaine with epinephrine group. 
In conclusion, this study shows that the addition of epinephrine to bupivacaine 
can partly counteract the vasodilatator effects of sympathetic blockade as well as the 
effects due to systemic uptake of bupivacaine and their influences on the cardiac con-
tractility. 
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CHAPTER 7 
CardiovascuUr effects af er lumbar epidural administration of 
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Abstract 
In a randomized double blind fashion twenty patients received 20 ml of 0.75% bupiv-
acaine or 20 ml 0.75% ropivacaine, both with 5 (ig.mH epinephrine for epidural 
anesthesia. Onset time and mean maximum level of sensory blockade were not differ-
ent in the two groups. Cardiovascular measurements were determined by a nonin-
vasive cardiac output monitor, the transthoracic electrical bioimpedance monitor. 
After epidural administration of 20 ml of either solution, the mean arterial blood 
pressures decreased significantly from control values, the decrease was more pro-
nounced in the bupivacaine group. Mean maximum decreases for bupivacaine and 
ropivacaine were 21% and 9.6% respectively, 20 minutes after epidural administra-
tion. Stroke volume and cardiac output increased significantly from control values. 
There were no significant differences between the two groups. The ejection fraction 
increased significantly from control values, two minutes after epidural administration 
of 20 ml bupivacaine 0.75% with epinephrine, whereas the changes in the ropivacaine 
group were not significantly different. The differences in the cardiovascular effects 
between the two groups are caused by the difference in their own vasoactive proper-
ties of bupivacaine and ropivacaine. 
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Introduction 
The potent cardiotoxic effects of the highly lipid soluble local anesthetic agent, 
bupivacaine, are well documented (Prentiss 1979, Mallampati 1984). This indicates 
the need for the development of an equally effective, but less cardiotoxic, local anes-
thetic agent. 
Ropivacaine is a new local anesthetic agent, with a chemical structure similar to 
that of bupivacaine (Rosenberg 1983). Previous studies in animals and humans sug-
gest that the cardiac toxicity of bupivacaine is greater than that of ropivacaine when 
given in equal doses on mg basis (Arthur 1988, Moller 1986, Reiz 1989, Bowler 1989). 
Ropivacaine and bupivacaine with epinephrine 5 (Jg.ml"1 are equally potent in 
terms of onset and duration of analgesia after epidural injection (Kerkkamp 1990a, 
chapter 10 ). However ropivacaine seems to produce less motor blockade after epi-
dural administration than bupivacaine (Feldman 1988, Kerkkamp 1990a). 
Cardiovascular changes were compatible with those associated with the autonomic 
blockade of epidural blockade (Kerkkamp 1990a, Feldman 1989). 
The cardiovascular effects of epidural anesthesia are complex and related to the 
level of anesthesia, the amount of anesthetic injected, the addition of epinephrine to 
the local anesthetic solution, and the cardiovascular status of the patient. 
Transthoracic electrical bioimpedance monitoring is a noninvasive method of 
measuring cardiac output that has been shown to correlate with cardiac output 
measured by thermodilution (Appel 1986, Bernstein 1986). The monitor measures the 
impedance to electrical current flow from the neck to the base of the thorax. This im-
pedance is a function of the blood volume of the chest and fluctuates with the cardiac 
output. This technique is useful in the research of the hemodynamic effects of anes-
thetic agents or procedures known to cause cardiovascular disturbances (McMenemin 
1988, Kerkkamp i990b). 
The aim of the present study is to determine the cardiovascular changes in relation 
to cpidurally administered bupivacaine and ropivacaine. 
Materials and methods 
Twenty patients (ASA physical status I or II) were entered into a randomized double 
blind study. The study was approved by the Human Ethical Committee of the 
University of Nijmegen. Informed consent was obtained from all patients prior to ad-
mission to the study. All patients were scheduled for elective surgery under epidural 
anesthesia. Excluded were patients with a history of neurological, cardiovascular or 
pulmonary disease and patients using cardiovascular medication. The patients were 
divided in two groups: group 1 received 20 ml 0.75% ropivacaine with 5 (Jg.ml"' epi-
nephrine and group 2 received 20 ml 0.75% bupivacaine with 5 |Jg.ml·' epinephrine. 
Premedication consisted of diazepam io mg, given orally 90 minutes before inser-
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ting the epidural catheter. All patients received 500 ml of a balanced electrolyte solu­
tion intravenously before epidural administration of the local anesthetic agent. 
With the patient in the lateral position and after infiltration of the skin with lido-
caine 1%, a 18 gauge Tuohy needle was introduced in the L2-3 or L3-4 interspace 
using the midline approach and the loss of resistance technique with air. An epidural 
catheter was then inserted 3 cm beyond the needle tip, and the patient was turned su­
pine, after securing the catheter. Before administration of the local anesthetic solu­
tion, a 15 minutes rest period was observed. Systolic, diastolic and mean arterial blood 
pressure were measured at 1 minute interval with an automatic blood pressure moni­
tor (E.M.E. Bristol Gardens, England). Hemodynamic measurements (heart rate, 
stroke volume, cardiac output and ejection fraction) were continuously obtained with 
the NCCOM-3 cardiodynamic monitor (Bomed Medical Manufacturing ltd., Irvine 
California, USA). 
Heart rate, blood pressure, stroke volume, cardiac output and ejection fraction 
measured five minutes before epidural injection, were used as pre-epidural injection 
control values. A test dose of 3 ml of either 0.75% ropivacaine or 0.75% bupivacaine 
both with 5 lig.ml-' epinephrine was administered. After four minutes a total dose of 
17 ml of the same solution was administered in incremental doses over four minutes. 
The total dose given was 150 mg ropivacaine or 150 mg bupivacaine respectively. 
The hemodynamic measurements were continuously monitored during 30 min­
utes after epidural injection in the supine position. The data are expressed as relative 
changes from the control values. The upper and lower levels of analgesia were deter­
mined bilaterally by pinprick with the blunt end of a Sherwood B400 27-gauge 
needle at 2 and then every 5 minutes after the end of the injection for 30 minutes. The 
levels of analgesia are segmentally recorded. All times given are from the end of the 
epidural injection. 
All parameters were compared within and between the two groups. The results 
were analysed using a t-test for paired or unpaired observations. A ρ value less than 
0.05 was considered statistically significant. 
Results 
Twenty patients participated in the study. The groups were comparable in age, height 
and weight (table 7.1). 
Onset and spread of analgesia 
The development of segmental blockade after the end of epidural administration of 
the local anesthetics is shown in figure 7.1. Statistical analysis indicate no significant 
differences for mean onset time and mean maximum cephaled level of analgesia 
which reached T6 for both groups. 
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Table 7 1 Demographic data (mean ± SEM) 
Ropivacaine 0 75% with epinephrine 
π=10 
Bupivacaine 0 75% with epinephrine 
n=10 
Age (years) 
Height (cm) 
Weight (kg) 
47(5) 
180(2) 
79(4) 
55(6) 
176(2) 
75(3) 
n= number of patients 
Table 7 2 Mean pre-blockade hemodynamic values (control values) with standard deviations between pa­
rentheses 
Ropivacaine 0 75% with epinephrine 
n=10 
Heart rate (bpm) 71(9) 
Systolic art blood pressure (mm Hg) 132(15) 
Diastolic art blood pressure (mm Hg) 80(10) 
Mean art blood pressure (mm Hg) 97(11) 
Stroke volume (ml) 97(24) 
Cardiac output (I/mm) 6 8( 1 6) 
Ejection fraction (%) 65(5 7) 
Bupivacaine 0 75% with epinephrine 
n-10 
73(12) 
133(18) 
83(9) 
99(11) 
79(24) 
5 5(1 5) 
60(6 5) 
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/•igure 7 / The onset of sensory blockade after epidural injection of 20 ml о 75% ropivacaine and 20 ml 
о 75% bupivacaine both with epinephrine. Values are means of segmental dermatomes + SEM. 
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Hemodynamic effects 
The absolute figures of the hemodynamic measurements (control values) before in­
jection of the local anesthetic drug are shown in table 7.2. 
Changes in heart rate are illustrated in figure 7.2. Two minutes after the end of the 
epidural administration the heart rate increased significantly in the ropivacaine 
group. In the bupivacaine group, the heart rate increased significantly after 5 minutes 
after the end of epidural administration. In contrast to the bupivacaine group, in the 
ropivacaine group the heart rate remained significantly elevated throughout the study 
period. The mean maximum relative change in heart rate was 22% in the ropivacaine 
group, 10 minutes after the end of epidural injection. The mean maximum relative 
change was 12% in the bupivacaine group after 10 minutes. The changes in heart rate 
between the two groups were not significantly different. 
5 _ 
ropivacaine 
bupivacaine time (min) 
Figure j.2: Changes in heart rate after epidural injection. Each point represents the mean (+ SEM) rela­
tive change from control values. T=o represents the values at the end of the epidural administrations. 
Significant differences within the groups are indicated by * . 
Changes in systolic blood pressure are shown in figure 7.3. Twenty five minutes after 
injection of the local anesthetic drug the systolic blood pressure decreased significant 
(-13%) from control values in the bupivacaine group. Clinical relevant hypotension 
(defined by a > 30% drop in systolic blood pressure from control values), requiring 
administration of intravenous drugs or supplementary fluid loading, was not experi­
enced in this study, although the decrease in systolic blood pressure was more marked 
in the bupivacaine group. 
8г 
ropivacaine 
bupivacaine time (mm) 
Figure 7 ) Changes in systolic blood pressure after epidural injection Each point represents the mean 
(± SEM) relative change from control values 1 =o represents the values at the end of the epidural injec­
tions Significant differences between the two groups are indicated by О 
-α 
с-, 
β 
ropivacaine 
bupivacaine time (min) 
figure 7 4 Changes in diastolic blood pressure Fach point represents the mean (± SEM) relative change 
from control values T=o represents the values at the end of the epidural administrations Significant dif­
ferences within the groups are indicated by · 
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Significant changes in diastolic blood pressure occurred in both groups after г minu­
tes. All values remained lower than control in both groups. No significant difFerences 
were found in diastolic blood pressures between the groups (figure 7.4). The decrease 
in the bupivacaine group was more pronounced than in the ropivacaine group. Mean 
arterial blood pressure changes are given in figure 7.5. In the bupivacaine group the 
mean arterial blood pressure decreased significantly after 2 minutes, the changes in 
the ropivacaine group were significant only after 20 minutes. 
hgure J5 Changes in mean arterial blood pressure Each point represents the mean (± SEM) relative 
change from control values T=o represents the values at the end of the epidural administrations 
Significant differences within the groups are indicated by # . Significant differences between the two 
groups are indicated by О 
Changes in stroke volume and cardiac output are illustrated in figures 7.6 and 7.7. 
Stroke volume increased significantly 2 and 5 minutes after the end of epidural admi­
nistration for the bupivacaine and ropivacaine group, respectively. Two minutes after 
the end of epidural injection cardiac output increased significantly from pre-blockade 
values in both groups. Stroke volume and cardiac output remained elevated through­
out the study period. Comparison between the two groups for both parameters, 
showed no significant differences. 
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ropivacaine 
bupivacaine time (min) 
Figure 7 6 Changes in stroke volume Each point represents the mean (± SEM) relative change from 
control values T=o represents the values at the end of the epidural administrations Significant differ­
ences within the groups arc indicated by * 
bupivacaine 
Figure 7 7 Changes in cardiac output Each point represents the mean (± SEM) relative change from 
control values T=o represents the values at the end of the epidural administrations Significant differ­
ences within the group are indicated by · 
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Figure 7.8 shows the relative changes in ejection fraction after the end of epidural in-
jection. Two minutes after the administration of bupivacaine with epinephrine the 
increase in ejection fraction was 5.5%. The maximum relative change in ejection frac-
tion in the bupivacaine group was 9%, which was a significant increase from control. 
Comparison of the ejection fractions between the two groups showed no significant 
differences. 
ropivacaine 
bupivacaine time (min) 
Figure 7.8: Changes in ejection fraction. Each point represents the mean (± SEM) relative change from 
control values. T=o represents the values at the end of the epidural administrations. Significant differ-
ences within the bupivacaine group are indicated by * . 
Discussion 
Ropivacaine and bupivacaine are effective local anesthetic drugs when used for epi-
dural anesthesia in man. Onset times for analgesia were similar in both groups. Other 
studies indicated a good differential blockade with regard to sensory versus motor for 
ropivacaine (Kerkkamp 1990a, Whitehead 1990). 
Differences in autonomic blockade of epidural anesthesia after administration of 
bupivacaine or ropivacaine are not known. However, cardiovascular effects associated 
with epidural anesthesia are not only attributed to a sympathetic blockade, but also to 
the type and dose of the local anesthetic agent, the added vasoconstrictor and the abil-
ity of the vascular system to compensate (Covino 1978). 
Although it is not statistically significant, the decrease in blood pressure is more pro-
nounced in the bupivacaine group, compared to the ropivacaine group. The differ-
So 
enees in blood pressure in the current study can be explained by the extent of sympa-
thetic blockade and the direct effects of the absorbed local anesthetics. In contrast to 
bupivacaine, ropivacaine is an effective vasoconstrictor (Kopacz 1988). 
The vasoconstrictor effects have also been demonstrated in epidural blood flow. 
Epidural blood flow decreased significantly after epidural administration of ropiv-
acaine (37%), compared with an increased blood flow after epidural administration 
with bupivacaine (17%) (Dahl 1990). In an animal study, drug concentrations of both 
ropivacaine and bupivacaine were measured after epidural administration. The peak 
bupivacaine concentrations occurred earlier than those of ropivacaine (Feldman 
1989). 
The increase in heart rate in the ropivacaine group was more pronounced com-
pared to the bupivacaine group. This can be related to the electrophysiological de-
pressant effects of bupivacaine. In an isolated rabbit purkinje fiberventricular muscle 
preparation, ropivacaine was less potent than bupivacaine in terms of its depressant 
effect on cardiac excitation and conduction (Moller 1990). 
Stroke volume and cardiac output increased significantly from control values in 
both groups. The changes are caused by the absorption of the epinephrine. This was 
demonstrated in a previous study (Kerkkamp 1990 , chapter 6). There were no signi-
ficant changes in stroke volume and cardiac output between the two groups. 
In a randomized, double blind study in human volunteers, the effects of intra-
venous administration of ropivacaine and bupivacaine on the left ventricular function 
were measured (Bowler 1989). The authors found significant differences in ejection 
fraction and stroke volume after the end of infusion (mean dose of ropivacaine 150 
mg and of bupivacaine 99 mg). The ejection fraction decreased 8% in the ropivacaine 
group and 10% in the bupivacaine group. In our study the patients received either 150 
mg ropivacaine or 150 mg bupivacaine both with epinephrine. Ejection fraction in-
creased significantly in the bupivacaine group two minutes after epidural administra-
tion. There were no significant changes in ejection fraction within the ropivacaine 
group. The hemodynamic effects of adding epinephrine to local anesthetics have 
been shown by several authors (Bonica 1971, Stanton-Hicks 1973, Otteson 1978, 
Kerkkamp 1989). In all those studies the cardiodepressive effects of the epidurally in-
jected local anesthetics were reduced or counteracted when a small amount of epi-
nephrine was added to the local anesthetic drug. The differences in ejection fraction 
between the two groups can be caused by the absorbed epinephrine. Because of the 
vasoactive properties of ropivacaine, the plasma epinephrine concentration is less in 
the ropivacaine group compared to the bupivacaine group. 
The results suggest that further investigations of ropivacaine and bupivacaine 
without epinephrine are necessary to determine more accurately the cardiovascular 
effects after their epidural administration. 
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CHAPTER 8 
Effects of epidurally and intrathecally administered ropivacaine 
and bupivacaine in rats 
H.E.M. Kerkkamp and R. Dirksen 
Parts of this chapter have been presented at the ESRA zone meeting, Nijmegen, The 
Netherlands, May 12, 1990 and at the IX. annual ESRA congress, Bern, Switzerland, 
September 5-8,1990. 
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Introduction 
Local anesthetics reduce the propagation of action potentials in excitable membranes. 
Since local anesthetics are injected near their sites of action (for instance the peripher-
al nerves), the effect will be a reversible blockade in transmission of impulses in that 
nerve. 
The potency, onset of action and duration are primarily determined by the physi-
cochemical properties of the various drugs (Concepción 1984). In addition to this, 
one other clinically important consideration is the ability of local anesthetic agents to 
cause a differential blockade of sensory, autonomic sympathetic and motor fibres 
(Rosenberg 1983). 
The investigation of the pharmacology of local anesthetics is performed with iso-
lated nerve preparations, in intact animals and in man. Animal studies with drugs af-
fecting nerve impulses have been performed in dogs, cats, guinea pigs, mice and rats. 
The technique to evaluate sensory blockade consists in evaluation of an attempt to 
withdraw the hind-legs in response to pinching of the foot-pads with an Allis tissue 
forceps. Complete motor blockade is defined as the inability to support the body 
weight with the hind legs (Akerman 1985). 
These techniques were used to determine the effects of ropivacaine and bupiv-
acaine (Akerman 1988, Feldman 1988). After intrathecal or epidural injection, the 
time that the animals were unable to stand on the hind-legs or responded to pinching 
of the food-pads was shorter after ropivacaine administration compared to bupiv-
acaine administration. In this study a recently developed animal model (Dirksen 
1990) was used to quantify and analyse the graded effects as a function of time after 
epidural or intrathecal administration of ropivacaine and bupivacaine. 
Experiments reported herein were approved by the committee on ethical aspects 
of laboratory animal care and use. 
Methods 
Male Wistar rats of the outbred strain Cpb:WU(CPB-TNO, Zeist, The Netherlands) 
weighing i50-300g were used for all the experiments. Pre-experimental conditions 
were standardized including manufactured food and tap water, housing conditions iz 
h. day/night cyclus and an environmental temperature of 210C. 
Epidural preparation 
The animals (n=i2) were anesthetized with enflurane vapour. The skin of the back 
was depilated, and the animal was mounted in a stereotomy instrument. A midline 
incision was made over the spinous processes of the lower three lumbar vertebrae and 
extended over the upper part of the sacrum bone. Identification of the lumbar verte-
brae was performed by palpation of the iliaca crests. The fascia covering the super-
93 
fidai muscles of the back was opened. The long superficial muscles were dissected 
from the vertebrae and bluntly retracted to expose the lamina of the vertebrae. After 
removing the spinous process of the fifth lumbar vertebrae a small hole was drilled 
into the lamina, which provided access to the lumbar epidural space. A Poly-ethylcne 
catheter was introduced to a length of ι cm. The tip of the catheter was located at the 
lumbar enlargement. A drop of Histoacryl tissue adhesive (Braun Melsungen, W-
Germany) sealed the space between the drilled hole and the catheter to prevent drug 
leakage. 
A loosely light knot in the catheter filled with dental cement was fixed into the 
wound to prevent catheter dislocation. The catheter was externalised subcutaneously 
on the top of the skull. A small piece of stainless-steel was inserted in the proximal 
end to close the Poly-ethylene catheter. 
Intrathecal preparation 
In rats under cnflurane anesthesia a polyethylene catheter (PE-io) was inserted into 
the lumbar subarachnoid space through an opening made into the atlanto-occipital 
membrane according to the procedure described by Yaksh and Rudy (1976). 
The catheter was externalised subcutaneously on the top of the skull. The PE-io 
catheter, prepared prior to surgery, had a loose knot tied at the point of exit from the 
cisterna and this was covered with a drop of dental cement. A small piece of tight-fit­
ting stainless-steel wire was inserted into the proximal end of the PE-io catheter to 
prevent backflow of cerebrospinal fluid. 
After cannulation of the subarachnoid or epidural space the animals were housed 
separately in a macrolon cage with sawdust bedding. Animals showing motor disturb­
ances were discarded from the study. 
Animal model 
After a recovery period of 7 days, a rat was anesthetized with intraperitoneal injection 
of urethrane (1.2 gr.kg-') to allow cannulation of the trachea (Abbocath 14G), the in­
ternal jugular vein and the carotid artery. Anesthesia was maintained by subcutaneous 
administration of urethrane 0.2 mg.kg-1. 
The rat was then positioned on the experimentation table and artificially normo 
ventilated with a semi-open electrical valve controlled small animal ventilator. The 
fresh gas flow was 0.5 ml.min-'.gr' bodyweight, and was kept constant throughout 
the experimental procedure in each animal. The body temperature was maintained 
between 36 and 37 0 C. 
A noxious electrical transcutaneous stimulus was given to the left hindpaw 
mounted in a shoe connected to the force transducer (grass FT 03C) that measured 
the force of withdrawal. The stimulus parameters were set to 4 ms pulse duration, 7.5 
mA stimulus strength, 100 Hz pulse frequency, in a train of 500 ms duration, and a 
repetition rate of 12.5 mHz (0.75 min-') for the trains (Grass stimulator S88 with sti­
mulus isolation unit SIU 5, and constant current unit CCU lA). 
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Determination of effects of the local anesthetic drugs started ι hour after fixating 
the animals on the table. 
Drug administration 
Ropivacaine and bupivacaine were obtained from Astra AJab AB, Sweden. The 
following doses of the respective drugs were given epidurally: 50 |il 0.75% ropivacaine 
with J lig.ml-' epinephrine and 50 |ДІ 0.75% bupivacaine with 5 μg.ml", epinephrine. 
For intrathecally admistration 10 μ] of the same solutions was used. After each injec­
tion the catheter was flushed with 10 μΐ NaCl 0.9%. 
The drugs were injected consecutively. The first drug to be injected was either 
bupivacaine or ropivacaine in a randomized order. Once the force of withdrawal had 
returned to the pre-injection magnitude (100% recovery), the second injection of a 
drug was given. The second drug was either ropivacaine or bupivacaine. Thus four 
groups can be distinguished (table 8.1). 
Table 8.1: Epidurally and intrathecally injected rats devided in four different groups. 
Group Number E/l First drug* Second drug** 
1 6 E бхЬирі асаіпе 4xrop¡vaca¡ne 
2 6 E бхгорі асаше 4xbup¡vacaine 
3 6 I бхЬирі асате бхгорі асаіпе 
4 6 I бхгорі асате бхЬирі асате 
E/l. epidural or intrathecal injection 
* number of rats injected with the first local anesthetic drug 
** number of rats injected with the second drug 
Data sampling and statistical analysis 
After one hour stabilisation of the animal, the individual baseline withdrawal force 
(expressed in g) was measured during 30 min. 
The average of the baseline responses was calculated and served to determine the indi­
vidual relative responses expressed as percentage of the baseline response (100%): 
withdrawal force 
Response (%)= - χ ιοο 
mean baseline withdrawal force 
Each animal served as its own control. Three parameters were used to quantify the in­
hibition of responses: The onset time (t0), defined as the time from the end of injec­
tion and the occurrence of 0% response. The time of complete blockade (t
c
), defined 
as the duration with 0% response. The duration of 50% recovery (t 5 0), defined as the 
time were the response returned to 50% of the baseline response. 
The results were analysed using a t-test for paired or unpaired observations. All re-
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suits are presented as means ± SEM. A ρ value less than 0.05 was considered statisti­
cally significant. 
Results 
Effects after epidural administration 
After epidural administration of ropivacaine or bupivacaine, the withdrawal re­
sponses to noxious electrical transcutaneous stimulation were completely inhibited 
(0% response). In four rats (two in each group) the second administration of a drug 
did not result in an inhibition of the withdrawal response. Postmortem examination 
of epidural injection with methylene blue revealed that leakage of the injected volume 
from the bore hole had occurred. The responses after epidural drug injections of the 
groups 1 and 2 are summarized in tables 8.2, 8.3 and 8.4. The figures 8.1 and 8.2 show 
the withdrawal responses as percentage of their controls (response %) as a function of 
time. 
There were no statistically significant differences in t 0 values assessed in group 1 
and group 2 after injection of the two drugs. The mean tc time after bupivacaine in­
jection (65.8 min) was significantly longer than that of ropivacaine (26.5min) in 
group 1 (table 8.2). 
Although the mean times of complete blockade of the second injection of either 
bupivacaine or ropivacaine were shorter compared to the first injection, it was not sta­
tistically different (table 8.3). The t 5 0 values after epidural injection of either ropiv­
acaine and bupivacaine are shown in table 8.4. The t values of group 1 and 2 were 
significant different in both group 1 and 2 in regard to the mean times for bupivacaine 
and ropivacaine. No statistically significant differences were found for t
 0 between 
group 1 and 2 in regard to the same local anesthetic agent. 
Table 8 2: Mean onset time (tg) and duration of complete blockade (te) in min after epidural administrations 
of 50 μΙ ropivacaine and bupivacaine 
Group 
1 
2 
1° 
2° 
1° 
2° 
1°= first injection 
2°= second injection 
SEM in brackets 
Drug 
bupivacaine 
ropivacaine 
ropivacaine 
bupivacaine 
(in consecutive to 1°) 
«0 
2 0(0 7) 
3 2(17) 
3 8(0 5) 
4 7(0 4) 
Ρ 
0 278 
0 121 
te 
65 8(6 4) 
26 5(6 3) 
33 2(4 3) 
42 8(8 3) 
Ρ 
0 003 
0 135 
9б 
Table 8 3° Mean onset time (tg) and duration of complete blockade It,.) in min after epidurally injection for the 
same local anesthetic agent in group 1 and 2 
Group Drug t 0 ρ t c ρ 
2 0(0 7) 65 8(6 4) 
0 126 0 082 
4 7(0 4) 42 8(8 3) 
3 8(0 5) 33 2(4 3) 
0 745 0 432 
3 2(1 7) 26 5(6 3) 
1 u 
2° 
1° 
2° 
bupivacame 
bupivacame 
ropivacaine 
ropivacaine 
10=first injection 
20=second injection (in consecutive to Io) 
SEM in brackets 
Table 8 4° ! „ values in min after consecutive epidural injections of 50 μ I bupivacame and ropivacaine. 
Group Drug 
I o bupivacame 84 6(6 7) 
0 005 
2° ropivacaine 44 5(4 8) 
1° ropivacaine 53 6(4 9) 
0 014 
2° bupivacame 80 5(5 1) 
1°= first injection 
2°= second injection (in consecutive to Io) 
SEM in brackets 
Table 8.5 Mean onset time (tg) and duration of complete blockade (tc) in min after intrathecally injection for 
the same local anesthetic agent in group 3 and 4 
Group 
3 
4 
1° 
2° 
I 0 
2° 
1°= first injection 
2°= second injection 
SEM in brackets 
Drug 
bupivacame 
ropivacaine 
ropivacaine 
bupivacame 
(in consecutive to 1°) 
<о 
1 0(0 6) 
1 6(0 6) 
4 2(0 5) 
2 8(0 7) 
Ρ 
0 175 
0 158 
tc 
23 0(6 4) 
12 5(2 9) 
10 2(3 6) 
15 5(6 4) 
Ρ 
0 005 
0 186 
97 
% 
jo -
Figure 81 Withdrawal responses as percentage of their controls (response %) as a ftinction of time after 
consecutive epidural injections of 50 (jJ bupivacaine and ropivacaine (group 1) I he middle curve repre­
sents the response, the upper and lower curve the SEM (bupivacaine B, ropivacaine R) 
50 -
Figure 8 2 Withdrawal responses as percentage of their controls (response %) as a function of time 
after consecutive epidural injections of 50 \Δ ropivacaine and bupivacaine (group i) The middle curve 
represents the response, the upper and lower curve the SbM (ropivacaine R, bupivacaine B) 
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Effects after intrathecal administration 
The responses for t 0, t c and t 5 0 after intrathecal injection of ropivacaine and bupiv­
acaine are summarized in the tables 8.5, 8.6, 8.7 and figures 8.3 and 8.4. 
The t 0 values (min) after injection of ropivacaine and bupivacaine were not diffe­
rent (table 8.5). The t
c
 values in group 3 were significant longer for bupivacaine (23.0 
min) compared to ropivacaine (12.5 min) (table 8.5). The t
c
 values in group 4 were not 
statistically different. 
No significantly differences were found in duration of complete blockade between 
bupivacaine in group 3 and 4, however the mean time tended to be longer in group 3 
(first injection). The x. values after intrathecal injection of bupivacaine and ropiv­
acaine are shown in table 8.7. The t 5 0 values are significant different in group 3. 
Table 8.6: Mean onset time (t0) and duration of complete blockade (tc) in min after intrathecally injection for 
the same local anesthetic agent in group 3 and 4. 
Group 
3 
4 
1°= first 
1° 
2° 
1° 
2° 
injection 
2°= second injection 
SEM in brackets 
Drug 
bupivacaine 
bupivacaine 
ropivacaine 
ropivacaine 
(in consecutive to 1°) 
to 
1 0(0.6) 
2 8(0.7) 
4 2(0.5) 
1.6(0 6) 
Ρ 
0.101 
0.102 
tc 
230(2.4) 
15.5(6.4) 
10.2(3.6) 
12.5(2.9) 
Ρ 
0.338 
0.660 
Table 8.7:T50 values in min after consecutive intrathecal injections of 10 μΙ bupivacaine and ropivacaine. 
Group Drug t« 
1° bupivacaine 
2° ropivacaine 
I o ropivacaine 
2° bupivacaine 
39 8(3.5) 
26 0(4.9) 
27.5(4.3) 
36.0(7.2) 
0.007 
0.393 
1 = first injection 
2°= second injection (in consecutive to Io) 
SEM in brackets 
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О 2 0 
time (min) 
Figure 8.3: Withdrawal responses as percentage of their controls (response %) as a function of time after 
consecutive intrathecal injections of to |il bupivacaine and ropivacaine (group 3). The middle curve rep­
resents the response, the upper and lower curve the SEM (bupivacaine: B, ropivacaine:R). 
% 
jo 
Figure 8.4: Withdrawal responses as percentage of their controls (response %) as a function of time after 
consecutive intrathecal injections of 10 |jl ropivacaine and bupivacaine (group 2). The middle curve rep­
resents the response, the upper and lower curve the SEM (ropivacaine: R, bupivacaine: B). 
Discussion 
Our study shows that both ropivacaine and bupivacaine inhibit the withdrawal re­
sponses elicited with noxious transcutaneous electric stimulation after epidural and 
intrathecal injection. 
Experimental models have been described in various animals to evaluate the effi­
cacy of new local anesthetic agents. After the originally described technique for intra­
thecal injection in the rat and mouse by Yaksh and Rudy (1976), many authors used 
the model for the evaluation of intrathecally injected drugs. The catheter technique 
has the advantage that comparative studies can be performed in one and the same ani­
mal. In all the studies complete sensory blockade is considered present if the animal 
does not vocalize or attempt to withdraw the hind legs in response to painful stimuli. 
Complete motor blockade is defined as inability to stand on the hind-limbs. 
Although such methods may provide information on the presence of sensory and 
motor blockade, it is obvious that a change of motor performance modifies the ability 
to respond to noxious stimuli for determination of sensory blockade. This means that 
the evaluation of sensory blockade is dependent on the regression of motor blockade. 
Besides this, graded responses after intrathecal or epidural injections of local anes­
thetics can not be detected. 
The model used in our study allows the measurement of graded responses to 
noxious stimuli. The model used in this study provides a useful method to evaluate 
the potencies of local anesthetics after epidural or intrathecal administration. The pe­
riod of complete blockade (t
c
) after epidural administration was significant longer for 
bupivacaine compared to ropivacaine in group 1. This difference was not found in 
group 2. The t
c
 values of each second drug tended to be shorter compared to the same 
drug when given as first drug. Consecutive injections of local anesthetics are known 
to exhibit a shorter lasting effect, a phenomenon referred to as tachyphylaxis. 
Tachyphylaxis of an effector response is known to develop when the intervals between 
administrations of local anesthetics are long enough to allow blockade to wear off 
completely. Due to this, one has to enhance the dose above that of its first in order to 
maintain the same effect of blockade (Bromage 1969). 
Comparison of the t 5 0 values after epidural injection shows more reproducible re­
sults compared to the t
c
 values. Statistical analysis between group 1 and 2 for bupiv­
acaine and ropivacaine respectively, indicates a faster return to 50% response for 
ropivacaine than for bupivacaine. 
The t
c
 values after epidural administration are longer compared to the t
c
 values 
after intrathecal administration, possibly due to the difference in injected doses (50 |il 
versus 10 |il for epidural and spinal injections respectively). 
Previous studies in dogs and guinea pigs suggest that intrathecally or epidurally in­
jected ropivacaine is less potent than bupivacaine in blocking neurons (Akerman 
1988, Feldman 1988). In these studies the anesthetic potency, defined as the amount of 
local anesthetic required to block to the same degree, after intrathecal injection is 1:1.5 
ιοί 
for bupivacaine and ropivacaine (Akerman 1988, Feldman 1988). When a similar 
comparison of potency is applied to our study, the potencies after intrathecally ad-
ministration at 50% recovery (t ) are for group 3 and 4,1:1.5 and 1:1.3 respectively. 
An in vitro study in isolated rabbit vagus nerves, indicated that ropivacaine ap-
pears to produce relatively less blockade of motor fibers than does bupivacaine but 
with similar sensory blockade (Bader 1989). Differences in pharmacology of local 
anesthetics such as onset of action, duration of action and potency can be explained 
by physical and chemical properties (Concepción 1984). Bupivacaine is more lipid 
soluble than ropivacaine in sciatic nerve and subcutaneous fat (Rosenberg 1983). The 
shorter duration of blockade after epidural and intrathecal injection and the differen-
ce in recovery with ropivacaine compared to bupivacaine may be due to a more rapid 
dissociation from nervous tissue due to its lesser affinity to lipids (Rosenberg 1986). 
In conclusion the animal model used in our study to evaluate local anesthetic po-
tency, provides more reliable information compared to "old" techniques. After epi-
dural and intrathecal administration in rats, ropivacaine is less potent than bupiv-
acaine in terms of inhibition of withdrawal responses after noxious stimulation. 
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Abstract 
Ropivacaine 0.5%, 0.75% and 1.0% with epinephrine 5 jJg.ml"1 was investigated in an 
open, multi-center study for lumbar epidural anesthesia in 46 patients undergoing 
urologie surgery. The onset time for analgesia to T12 was 5-7 minutes after the end of 
the ropivacaine injection. Maximum segmental levels of analgesia (T4-6) were not 
different between the groups. Complete motor blockade was obtained in 3/15, 7/15 
and 10/15 patients in the 0.5%, 0.75% and 1.0% groups, respectively. Duration of 
analgesia at the Tío level was 2.5 hours in the 0.5% group, and increased to 4 hours in 
the 1.0% group. Analgesia was satisfactory for surgery in all patients except for 2/15 in 
each of the 0.5% and 0.75% groups and 1/15 in the 1.0% group. Hypotension was ex-
perienced by three, six and three patients in the 0.5%, 0.75% and 1.0% groups respec-
tively. Bradycardia was seen in two patients in the 0.5% group and in one patient in 
the 1.0% group. Backache was experienced by seven patients (four in the 0.5%, two in 
the 0.75% and one in the 1.0% group). No late occurring adverse experiences were 
observed. In conclusion 0.5%, 0.75% and 1.0% ropivacaine with epinephrine provide 
adequate analgesia and motor blockade for urological surgery. 
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Introduction 
Ropivacaine is the (S)-enantiomcr of i-propyl-2',6'-pipecoloxyIidide, a new amide-
type local anesthetic agent with a chemical formula similar to that of bupivacaine and 
mepivacaine. If animal data can be used to extrapolate local anesthetic potency to 
man, ropivacaine seems to provide a greater margin of safety than bupivacaine (Reiz 
1989). 
When used for epidural anesthesia in the dog, 1.0% ropivacaine seems comparable 
to 0.75% bupivacaine (Akerman 1988). There is also evidence both from in vitro and 
in vivo studies that the cardiotoxic potential is lower with ropivacaine as compared to 
bupivacaine (Moller 1986). Consequently, ropivacaine might provide advantages over 
bupivacaine when used for epidural anesthesia in man. 
The present study was initiated to evaluate the clinical efficacy of ropivacaine in 
different concentrations with epinephrine added when used for epidural anesthesia. 
Methods 
This nonrandomized, open multi-center study was approved by the ethics commit-
tees of each of the three institutions that took part in the study. Informed consent 
(according to the Helsinki declaration) was obtained from 46 ASA I-II patients, 
scheduled to undergo urologie surgery under epidural anesthesia. 
The series began at each institution, with five patients being given 0.5% ropiv-
acaine, after which 5 patients were given 0.75% ropivacaine, and finally 1.0% ropiv-
acaine was administered to five patients. All ropivacaine solutions contained epineph-
rine 5 (Jg.ml-'.The solutions were manufactured by Astra Pain Control (Södertälje, 
Sweden). 
Premedication consisting of 10-20 mg diazepam was given orally 90 minutes prior 
to anesthesia. A balanced electrolyte solution (500 ml) was given before the adminis-
tration of ropivacaine. At each institution the epidural blockade was performed by 
one investigator and the efficacy assessments were performed, after injection, by 
another investigator during the entire study period. 
With the patient in the lateral decubitus position and after infiltrating the skin 
with local anesthesia, a 16 or 18 gauge Tuohy needle was introduced in the L2-3 or L3-
4 interspace using the midline approach and the loss-of-resistance technique with air. 
An epidural catheter was inserted approximately 3 cm cephalad and the patient was 
turned to the supine position. A test dose of 3 ml of lidocaine 1.0% with epinephrine 
(5 (ig.ml"1) was injected. Approximately 4 minutes after the test dose, 5 ml of one of 
the ropivacainc solutions was injected every minute to a total of 20 ml. The level of 
analgesia was tested segmentally with a blunt needle every 2-5 minutes for approxi-
mately 30 minutes and then every 15-30 minutes after the end of the injection of the 
main ropivacaine dose. The degree of motor blockade was evaluated using the 
Bromage scale (Bromage 1965). 
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Heart rate and blood pressure were monitored prior to and during the anesthesia. 
Cardiovascular effects, which included any episode of hypotension (as defined by 
а>зо% drop in pre-block systolic blood pressure, or a systolic blood pressure < 90 mm 
Hg) or bradycardia (defined as a heart rate of less than 50 beats per minute), were re­
corded and treated according to standard anesthetic practice. 
Statistical analysis was performed using analysis of variance and if^ < 0.05, it was 
followed by Wilcoxon's rank sum test, and the difference between proportions was 
determined by Chi-square test; ρ < 0.05 was considered statistically significant. 
Results 
Forty-six patients, 45 male and one female, took part in the study. One patient was 
excluded from the efficacy evaluations because of technical failure. For demographic 
data see table 9.1. The groups were comparable in age, height and weight. All the 
times given are from the end of the ropivacaine injection. 
Onset of analgesia and motor blockade 
The mean onset time for analgesia to the T12 level was 5-7 minutes after the end of in­
jection of all ropivacaine concentrations. There is a low power to detect differences 
between onset times at any segmental level. At the T12 level, the standard deviation of 
onset is about 3 minutes. The mean difference between onset times would have to 
have been larger than approximately 4 minutes to have a power of 90% to achieve sig­
nificant differences. 
In this study, onset time was measured with a precision of about 5 minutes. Hence, 
differences between onset times of a few minutes are difficult to detect. No significant 
differences in onset times were found between the three groups at any segmental level 
(figure 9.1). No significant differences were found between the groups in the mean 
maximum level of analgesia (T4-6) or the time to reach it (30-45 minutes). 
Table 9.1 : Demographic data (mean ± SEM). 
Ropivacaine concentration with epinephrine 
0 5% 0 75% 1 0% 
(n=15) (n=15) (n=15) 
Age (years) 60(13) 57(14) 57(14) 
Sex Of/15m If/14m Of/15m 
Height (cm) 178(7) 176(9) 176(8) 
Weight (kg) 80(7) 80(12) 80(17) 
n=number of patients 
f=female 
m=male 
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Complete motor blockade (of both legs) was obtained in three out of 15 patients in 
the 0.5% group, in seven of 15 patients in the 0.75% group and ten of 15 patients in 
the 1.0% group, and the difference between the 0.5% and the 1.0% groups was signi­
ficant. Onset to complete blockade (i.e. degree 3 on the Bromage scale) was 53 minu­
tes in the 1.0% group (median value). 
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• ropivacaine 0.5% 
Ы ropivacaine 0.75o/ 
И ropivacaine 1.0% 
L2 T12 Tío T8 T6 T4 
Figure p.i: Onset of analgesia, mean + і.дбх SEM, approximate 95% confidence interval. 
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Figure 9.2: Segmental level of analgesia, median values. The upper level of analgesia is significant higher 
3-5 hours in the 1.0% group and 1.5-3.5 hours in the 0.75% group after the epidural injection, compared 
to the 05% group. 
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CephaUd and caudal Uvei of analgesia 
The cephalad level of analgesia was significantly higher in the 1.0% group from 3 to 5 
hours after the end of the injection, and in the 0.75% group 2.5, to 3.5 hours after in-
jection, both compared to the 0.5% group. No differences were found at any time be-
tween the 0.75% and the 1.0% groups (see figure 9.2). The S5 segment was blocked in 
43/45 patients. 
Duration of analgesia and motor blockade 
Duration of analgesia increased with increasing ropivacaine concentration: at Tío, 
analgesia lasted from 2.5 hours (0.5% ropivacaine) to 4 hours (1.0% ropivacaine); at 
L2 for 3.5-4.5 hours; at L5, 3.5-5 hours, and at S5, 3.5-5.5 hours (figure 9.3). 
The duration in the S1-3 segments, in the lumbar segments and the lower thoracic 
segments (Tio-i2) was significantly longer for 0.75% and 1.0% ropivacaine compared 
to 0.5% ropivacaine. The 1.0% solution also produced a significantly longer duration 
of analgesia than 0.5% ropivacaine at S5. 
Duration of motor blockade also increased with increasing ropivacaine concen-
tration: duration of degree 2 motor blockde increased from 2 hours in the 0.5% group 
to 3 and 3.5 hours in the 0.75% and 1.0% groups, respectively (figure 9.4). 
Ropivacaine 1.0% produced a significantly longer duration of all degrees of motor 
blockade compared to the 0.5% solution, and significant differences were also found 
between the 0.75% and 0.5% groups for the degrees 2 and 3. No significant differen-
ces were found between the 1.0% and the 0.75 groups. 
S5 S3 Si L5 Lz T12 Tío T8 T6 T4 
Π ropivacaine 0.5% 
CSI ropivacaine 0.75% 
И ropivacaine 1.0% 
Figure p.3: Duration of analgesia at different segmenta! levels: mean ± 1.96 χ SEM, approximate 95% 
confidence interval. At the S1-3, lumbar and low thoracic segments the duration of analgesia is signifi­
cant longer for the 0.75% and 1.0% group compared to the 0.5% group. 
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Figure Ç.4: Duration of different degrees of motor blockade of the lower limbs: mean ± 1.96X SEM, ap-
proximate 95% confidence interval. There is a significant difference in duration of all degrees motor 
blockade for the 1.0% group, compared to the 0.5% group. There is a significant difference between the 
0.75% and 0.5% groups for the degrees 2 and 3 motor blockade. 
Cardiovascuhr effects 
No clinically relevant diflferences were found between the groups in regard to the 
changes in heart rate or mean arterial blood pressure (figures 9.5 and 9.6). 
Hypotension requiring intravenous ephedrine was experienced by three patients in 
each of the 0.5% and 1.0% groups and by six patients in the 0.75% group. Bradycardia 
requiring atropine was seen in two patients in the 0.5% group and in one patient in 
the 1.0% group. Nausea and ventricular ectopic beats each were experienced by one 
patient in the 1.0% group. 
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Figure p.$: Relative changes in heart rate during the first 30 minutes after injection, mean ± 1.96 χ SEM, 
approximate 95% confidence interval. 
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Figure ρ 6 Relative changes in mean arterial blood pressure (MAP) during the first 30 minutes after in­
jection, mean ± 1 96 χ SEM, approximate 95% confidence interval. 
Quality of surgical anesthesia 
Surgery was undertaken after 11-138 minutes (mean, 47) and surgical time was 12-120 
minutes (mean, 44). Analgesia was satisfactory in all patients except 2/15 in each of 
the 0.5% and 0.75% groups and 1 of the 1.0% group. Two of these were given either 
fentanyl or nothing for the pain; one, N2O/O2, and two, N2O/O2 with isoflurane at 
the end of surgery. 
Adverse events 
Backache (or back pain) was experienced by seven patients (four in the 0.5% group, 
two in the 0.75% group and one in the 1.0% group). One patient (given 0.75% ropiv­
acaine) suffered from headache. Breathing difficulties, due to the high block, were re­
ported from one patient in the 0.5% group and shivering was seen in six patients 
(three in the 0.5% group, one in the 0.75% group and two in the 1.0% group). 
All adverse experiences were mild or moderate, and all patients recovered comple­
tely. All patients were questioned on the sixth day (or later) after surgery for possible 
neurologic disturbances or other late complications that may have been related to the 
blockade, in no case was any late complication reported. 
Discussion 
When a fixed volume of a local anesthetic is injected cpidurally, an increase in con­
centration of the drug normally results in a more profound block, with a more rapid 
onset and increased duration of analgesia (Littlewood 1977). However, increasing the 
concentration (and dosage) may also lead to systemic toxicity. Consequently, an opti­
mal concentration exists. Increasing the concentration above this optimal concentra­
tion produces little or no further degree of conduction blockade (Scott 1980). 
For onset of analgesia or motor blockade, maximum cephaled spread or frequency 
of S5 dermatome blockade no difference could be verified in any of these three drug 
concentrations. On the other hand, a higher frequency of complete motor blockade 
was obtained in the 1.0% group as compared to the 0.5% group. After epidural 
administration of any local anesthetic, duration of analgesia (and motor blockade) 
should be expected to be dose dependent, as has been shown with bupivacaine, 
etidocaine and prilocaine (Littlewood 1977). In the present study, significant differen­
ces in duration of analgesia were found between 0.5% ropivacaine and 0.75% or 1.0% 
ropivacaine but not between 0.75% and 1.0% ropivacaine. Wether this is due to low 
statistical power or to the vasoactive properties of ropivacaine and whether these arc 
dose (or concentration) dependent remains to be shown in future studies (Akerman 
1987, Kopacz 1988, Forsberg 1988). 
Cardiovascular changes as observed in this study were not different from what has 
been seen in other epidural studies, with other agents, and in none of the patients 
were unusual electrocardiographic effects recorded. The present study demonstrates 
ropivacaine to be a useful local anesthetic for epidural anaesthesia: the blocks pro­
duced adequate surgical anesthesia in 40 out of 45 patients, and the failures were 
equally distributed between the groups. 
To conclude, in this open study, 20 ml of 0.5%, 0.75% and 1.0% ropivacaine with 
5 μβ.ιηΗ epinephrine has been shown to produce adequate surgical anesthesia and 
motor block for urologie surgery. 
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Abstract 
Forty-three ASA physical status I and II patients, scheduled for elective urologie 
surgery, were randomly entered into a randomized double-blind study using 20 ml 
bupivacaine 0.75% or 20 ml ropivacaine 0.75%, both with 5 μβ.πιΐ"1 epinephrine. 
Two patients were excluded from evaluation of efficacy due to technical failure. After 
a test dose of 3 ml bupivacaine 0.75% with epinephrine or ropivacaine 0.75% with 
epinephrine, 17 ml of either solution was given in incremental doses over 4 minutes 
(4, 4, 4 and 5ml). Analgesia was satisfactory for surgery in all patients except for one in 
each group. The onset time of analgesia was short: after administration of ropiv­
acaine and bupivacaine, the T12 dermatome was blocked within 6-8 minutes. Mean 
maximum upper level of analgesia was similar in the groups -T8±o.6 and T7±o.6 
(mean + SEM)- for ropivacaine and bupivacaine, respectively. Duration of analgesia 
at the Tío level was 190+12 minutes in the ropivacaine group and 234+7,0 minutes in 
the bupivacaine group and was significantly shorter for ropivacaine at Tío, L2 and S5 
segments. Frequency of complete motor block was significantly lower in the ropiv-
acaine group (7/21) than in the bupivacaine group (16/20). No differences were found 
in onset to various degrees of motor block, however, the duration of degree 1 motor 
block was significantly shorter in the ropivacaine group. Hypotension and brady-
cardia requiring treatment were experienced by seven and three patients, respectively, 
in the bupivacaine group, and by two and one patient, respectively, in the ropivacaine 
group. No postoperative adverse events related to anesthesia were observed. 
Ropivacaine 0.75% with epinephrine is an effective long-acting local anesthetic. 
Duration of sensory block is similar to that of bupivacaine 0.75% with epinephrine; 
however, the motor block is less profound and of shorter duration. 
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Introduction 
Ropivacaine, a new amino amide local anesthetic agent, is the pure (S)-enantiomer of 
a chain shortened analog of bupivacainc (propyl instead of butyl side chain). Animal 
experiments have suggested that ropivacaine is less cardiotoxic than bupivacaine and 
may also possess a greater safety margin between the convulsant and lethal doses (Reiz 
1989, Morishima 1985, Pederson 1988). 
Additional animals studies have indicated that ropivacaine has an anesthetic 
profile similar to that of bupivacaine, although ropivacaine 0.75% has a shorter du-
ration of motor block than bupivacaine 0.75% (Arthur 1988, Feldman 1988, 
Morishima 1985). 
In a number of open clinical studies, epidural administration of ropivacaine 
0.75%, without and with epinephrine, has resulted in satisfactory surgical analgesia, 
although the degree of motor block has been less marked (Conception 1989, Katz 
1989, Kerkkamp 1990, Thomson 1989) than with bupivacaine. No comparative 
studies in humans have yet been reported. This randomized, double-blind study 
examined the neural block characteristics of 20 ml of 0.75% solutions of ropivacaine 
and bupivacaine, both with epinephrine, after epidural administration in humans. 
Methods 
Forty male and three female patients of ASA physical status I and II were entered into 
a randomized double-blind study of ropivacaine and bupivacaine that had been ap-
proved by the institution's Human Ethics Committee. Two male patients (in the 
bupivacaine group) were excluded from evaluation of efficacy due to technical 
failures. Informed consent was obtained from all patients prior to admission into the 
study. All patients were scheduled for elective urologie surgery under epidural anes-
thesia. Excluded were patients with a history of significant neurologic, cardiopulmo-
nary, and psychiatric disease, patients with a history of drug abuse, and women of 
childbearing potential. 
Premedication consisted of 5-10 mg diazepam given orally about 90 minutes prior 
to the induction of anesthesia. All patients received at least 500 ml of balanced elec-
trolyte solution intravenously before administration of the epidural block. Lumbar 
epidural puncture was performed at the L2-L3 or L3-L4 interspace with the patient in 
the lateral position. The epidural space was identified by a loss-of-resistance tech-
nique with air using an 18G Tuohy needle via the midline approach. An epidural 
catheter was inserted 3 cm cephaled and the patient was turned supine. 
A test dose of 3 ml of either ropivacaine 0.75% or bupivacaine 0.75% (Astra Pain 
Control, Södertälje, Sweden), both with 5 (Jg.mH of epinephrine, was given. After 3-4 
minutes, a total dose of 17 ml of the same solution as was used for the test dose was in-
jected in incremental doses over approximately 4 minutes. The total dose given was 
»7 
150 mg ropivacaine and bupivacaine, respectively. The epidural block was performed 
by one investigator (MJMG) and the assessments of efficacy by another investigator 
(HEMK). 
The upper and lower levels of analgesia were determined bilaterally with the blunt 
end of a Sherwood B400 27G short bevel needle at 2 minutes, and then every 5-
minutes after the end of the injection of the last dose for 30 minutes, and every 15-30 
minutes thereafter until normal sensation had completely returned. 
Motor block was assessed by use of a modified Bromage scale after each determi-
nation of analgesia (3= unable to flex hip, knee or ankle; 2= able to dorsiflex ankle 
only; 1= able to flex knee and ankle; 0= able to raise extended leg off bed). 
Heart rate was obtained from continuous ECG monitoring and blood pressure 
from an automatic cycling blood pressure recording device (Dinamap, Criticón, 
Tampa, USA) immediately prior to block, at 2, 5, 10, 15, 25 and 30 minutes after ini-
tiation of the block, and then every 30 minutes for 3 hours. Cardiovascular effects, 
which included any episode of hypotension (>зо% decrease from pre-block systolic 
blood pressure) or bradycardia (heart rate < 50 bpm) were recorded and treated 
according to standard anesthetic practice. 
The intensity and outcome of any adverse event during hospitalization was re­
corded. All patients were contacted between the sixth and 14th day after surgery to see 
wether any late complications had occurred. Interval data are expressed as mean 
(onset and duration of analgesia, onset and duration of motor block, changes in heart 
rate and arterial pressure) and ordinal data as median (segmental levels of analgesia). 
Statistical analysis for differences between distributions were analyzed by 
Wilcoxon's rank sum test, and differences between frequencies by chi-square or 
Fisher's exact test. A/»value less than 0.05 was considered significant. 
Results 
Twenty-one patients received 20 ml ropivacaine 0.75% with epinephrine and 20 pa­
tients were given 20 ml bupivacaine 0.75% with epinephrine. Demographic data are 
summarized in table 1. The groups were comparable in age, height and weight. All 
times given are from the end of the epidural injection. 
Quality of surgical anesthesia 
Duration of surgery was 55 + 6 (mean ± SEM) minutes in the ropivacaine group and 
70 + 9 minutes in the bupivacaine group. Analgesia was satisfactory for surgery in all 
patients but two, one in each group who required general anesthesia due to pain from 
surgery. They were given fentanyl, pentothal, and a combination of oxygen, nitrous 
oxide and isofluranc. 
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Onset of analgesia and motor bbck 
Mean time to reach the maximum upper level of analgesia was 20.1 ± 1.2 minutes for 
ropivacaine and 21.8 ± 1.8 for bupivacaine. The mean onset to T12 was 7.9 ± 0.7 
minutes for ropivacaine and 6.8 ± 0.6 minutes for bupivacaine. The mean onset time 
to block Si was 4.6 ± 0.7 minutes for ropivacaine and 4.7 ± 0.6 minutes for bupiv-
acaine. No differences were found between the groups in onset either to maximum 
upper segmental spread or to any segment. Nor were any significant differences 
found between the groups with regard to onset to various grades of motor block of 
the lower limbs. However, the frequency of degrees 2 and 3 (complete) motor block 
was significantly lower in the ropivacaine group (table 2). 
Table 10.1: Demografie data (mean ± SEM). 
Age (years) 
Sex 
Height (cm) 
Weight (kg) 
Ropivacaine 0.75% 
(n=21) 
42.6(3 0) 
2f/19m 
179.6(1.5) 
79.2(2.2) 
Bupivacaine 0.75% 
(n=20) 
52 9(3 3) 
1f/19m 
177 0(1 5) 
76.6(1 7) 
n= number of patients 
f= female 
m= male 
Table 10.2: Frequency of different degrees of motor block of the lower limbs. 
Degree of 
motor blockade 
1 
2 
3 
NS= not significant 
n= number of patients 
Ropivacaine 0.75% Bupivacaine 0.75% 
(n=21) (n=20) 
20/21(95.2%) 20/20(100%) 
15/21(71.4%) 20/20(100%) 
7/21(33.3%) 16/20(80%) 
Level of significance 
NS 
p<0.05 
fxO.OI 
Spread of analgesia 
Median upper and lower segmental levels of analgesia at various time intervals after 
injection are summarized in figure 10.1. Mean maximum upper level of analgesia was 
T8 ± 0.6 for ropivacaine and T7 + 0.6 for bupivacaine. The range was T3-T10 and 
T3-T9, respectively. The level of analgesia was higher for bupivacaine, but only at 5 
hours after injection. All patients but one (in the ropivacaine group) had block of the 
S 5 dermatome. 
Duration of analgesia and motor block 
Mean duration for Tío, L2 and S5 was 190 ± 12, 289 ± 11 and 430 ± 18 minutes for 
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ropivacaine, respectively, and 234 ± 20, 331 ± 18 and 496 ± 26 minutes for bupivacaine, 
respectively. However, at these levels the duration was shorter in the ropivacaine 
group compared to the bupivacaine group (figure 10.2). Ropivacaine produced a sig-
nificantly shorter duration of degree 1 motor blockade (252 ± 19 minutes) than bupiv-
acaine (320 ± 23 minutes). In no patient did the motor block last longer than the sen-
sory blockade. 
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Figure 10.1: Segmental levels of analgesia at different time intervals after the end of the epidural injection 
(median, upper and lower level). There is a significant difference between the groups 5 hours after injec-
tion. 
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Figure 10.2: Duration of analgesia at different time intervals after the end of injection (mean ±1.96 χ 
SEM, approximate 95% confidence interval). There is a significant difference between the groups at the 
Tío, L2 and 5 segments. 
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Cardiovascuhr effects 
No diflferences were found between the groups with regard to relative changes in heart 
rate or mean arterial pressure during the first 30 minutes after injection (figures 10.3 
and 10.4). Hypotension requiring administration of intravenous ephedrine was expe­
rienced by 2 out of 21 (9%) patients in the ropivacaine group and by seven out of 20 
(35%) patients in the bupivacaine group. Three patients in the bupivacaine group 
(15%) experienced bradycardia. In one patient given ropivacaine, manipulation with­
in the bladder resulted in a vasovagal reaction with resultant bradycardia. 
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Figure 10. j • Relative changes in heart rate at different time intervals after the end of injection (mean ± 
1,96 χ SEM, approximate 95% confidence interval). 
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Figure 10.4: Relative changes in mean arterial blood pressure at different time intervals after the end of 
injection (mean ± 1.96 χ SEM, approximate 95% confidence interval). 
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Adverse events 
Shivering after injection of the local anesthetic occurred in one patient and mild 
backache was experienced by two patients, all in the bupivacaine group and on the 
first day after surgery. All patients made a complete recovery. No late occuring adverse 
events were observed in any patient. 
Discussion 
All currently available local anesthetics have advantages and disadvantages. 
Bupivacaine provides sensory analgesia at relatively low concentrations without pro-
ducing profound motor block of the lower limbs, which makes it a very useful agent 
for obstetric anesthesia and for certain acute postoperative pain and chronic pain sta-
tes where prolonged sensory analgesia with minimal motor involvement is wanted. 
After unintentional intravenous administration of bupivacaine, however, cardio-
vascular collapse with fatal outcome has been reported (Albright 1979). Previous 
studies in animals do suggest that the cardiotoxicity of bupivacaine is greater than 
that of ropivacaine when used in equal doses (Arthur 1986, Moller 1986). Ropivacaine 
appears to provide a greater margin of safety than does bupivacaine when used in 
equal dosage (Reiz 1989). 
Our investigation has demonstrated that ropivacaine 0.75% is an effective long-
acting local anesthetic agent after epidural administration. No differences were found 
between ropivacaine and bupivacaine in onset of analgesia and motor block, spread of 
analgesia or quality of surgical anesthesia although duration of analgesia was shorter 
in the ropivacaine group at Tío, L2 and S5 dermatomes. 
Significantly fewer patients had degree 2 and 3 motor block after administration of 
ropivacaine compared to bupivacaine. Duration of degree 1 motor block was shorter 
in the ropivacaine group compared to the bupivacaine group. This is in accordance 
with studies in animals that have shown ropivacaine to be a less potent drug than 
bupivacaine in terms of producing motor block after epidural administration 
(Feldman 1988). 
Comparison of the physicochemical properties of ropivacaine and bupivacaine 
shows that the pKa values are almost identical (bupivacaine: 8.10, ropivacaine 8.07) 
and the ratio between the ionized cation and unionized base at physiological pH is si-
milar for the drugs. Ropivacaine, however, is less lipid soluble than bupivacaine 
(Rosenberg 1986). The greater lipid solubility of bupivacaine should have a major role 
in penetration of the large myelinated A fibers and may be the explanation of the dif-
ferences we have seen between ropivacaine and bupivacaine with regard to motor 
block (Narahashi 1971). 
Differential nerve block is of importance for the usefulness of a local anesthetic in 
the clinical situation. Ropivacaine may be better suited than bupivacaine for obstetric 
analgesia and for postoperative pain relief than for surgery requiring profound muscle 
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relaxation. How epinephrine affects the sensoiy/motor separation of ropivacaine and 
how it interacts with the vasoactivity of ropivacaine is not yet clear (Akerman 1987, 
Kopacz 1988). In the present study, no signs of significant cardiovascular depression, 
adverse events, or signs of toxicity were experienced. Transient hypotension occurred 
in 9% of the patients in the ropivacaine group and in 35% in the bupivacaine group 
and was readily corrected with intravenous administration of ephedrine. The magni-
tude of mean arterial blood pressure changes after administration of bupivacaine was 
similar to that reported by other investigators (Whalley 1987). 
In conclusion, ropivacaine 0.75% with epinephrine is an effective, long-acting 
local anesthetic when used for epidural anesthesia for urologie procedures. The du-
ration of analgesia is similar to that of bupivacaine although the motor block is less 
profound and of shorter duration. 
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CHAPTER ι describes the aims and objectives of this thesis entitled: "Ropivacaine ver­
sus bupivacaine, characteristics and clinical aspects in lumbar epidural blockade". 
CHAPTER 2 outlines briefly the history, physicochemical properties and mechanisms 
of action of local anesthetics. Because the physicochemical properties of local anes­
thetics are responsible for the clinical profile of these drugs, this chapter deals with 
molecular weight, lipid solubility, pK and protein binding in particular. 
CHAPTER З deals with the structural differences between ropivacaine and bupivacaine. 
By means of X-ray diffraction techniques an attempt is made to provide an insight 
into the 3-dimensional structure of the active forms of both ropivacaine and bupiv­
acaine. After a brief introduction to the basis for this technique, the results of this ex­
perimental study are discussed. Although the structure of ropivacaine and bupiv­
acaine differ only by a CH3 group, the molecular packing arrangements are different. 
CHAPTER 4 concerns a study of the literature on the cardiovascular effects of epidural 
blockade. Cardiovascular alterations following epidural blockade are related to the 
type and dosage of the administered local anesthetic, the addition of vasoconstrictors, 
the extent of the sympathetic blockade and the cardiovascular status of the patient. 
CHAPTER 5 describes the technique of noninvasive monitoring by electrical bioimpe-
dance. To begin with, basic principles of the circulatory system are shown. Historical 
features are presentcd.Then the development of the mathematical formulas used to 
calculate stroke volume are discussed. The calculations are based on rhythmic varia­
tion in thoracic electrical bioimpedance induced by fluctuations in the caliber of the 
large vessels and the flow of the blood in these vessels. 
CHAPTER 6 describes the hemodynamic effects in epidural blockade after administra­
tion of bupivacaine with and without epinephrine. Changes in hemodynamic perfor­
mances occurred within two to four minutes. Cardiac output, stroke volume and end 
diastolic volume increased in the epinephrine group. The differences are explained by 
the vasoactive effects of epinephrine. 
CHAPTER 7 deals with the hemodynamic effects in lumbar epidural blockade with 
ropivacaine and bupivacaine, both with epinephrine. The hemodynamic differences 
found in this study are related to the vasoactive properties of ropivacaine. 
CHAPTER 8 reports on an experimental study in rats, which involved the inhibition of 
withdrawal responses after epidural and intrathecal administration of bupivacaine 
and ropivacaine. Several experimental models are used to evaluate the efficacy of local 
anesthetics. The model used in this study allows the measurement of graded re­
sponses. After epidural and intrathecal administration, ropivacaine is less potent than 
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bupivacaine in terms of inhibition withdrawal responses, after noxious stimulation. 
CHAPTER 9 describes an open multi-center study to evaluate the clinical efficacy of 
ropivacaine in different concentrations (0.5%, 0.75% and 1.0%, with epinephrine) 
when used for epidural anesthesia. No differences in onset times were found between 
the three concentrations. The degree and duration of motor blockade increased with 
increasing ropivacaine concentration. Duration of analgesia increased with increasing 
ropivacaine concentration. This study as demonstrated that ropivacaine is an effec-
tive, long-acting local anesthetic agent when administered in the epidural space in 
man. 
CHAPTER 10 describes the neural blockade characteristics of 0.75% bupivacaine and 
0.75% ropivacaine following epidural administration in forty three patients. No dif-
ferences were found between the groups, neither in terms of onset time to maximum 
upper levelof sensory blockade nor in terms of onset time to any segment. Motor 
blockade is less profound and of shorter duration after ropivacaine administration 
compared to bupivacaine. The duration of analgesia was shorter in the ropivacaine 
group at Tío. Analgesia was satisfactory for surgery in both groups. 
Conclusions 
Epidural blockade has achieved wide popularity as a means to provide excellent surgi-
cal anesthesia and postoperative analgesia. This popularity is a result of the develop-
ment of local anesthetics with long duration and good sensory blockade. 
Bupivacaine was the first local anesthetic agent that combined the properties of an 
acceptable onset, long duration of action, profound blockade and separation of sen-
sory and motor blockade. However, there has been considerable concern regarding 
the untoward cardiovascular effects after accidental intravenous administration of 
bupivacaine. 
Ropivacaine is a new local anesthetic which has been shown to be less toxic com-
pared to bupivacaine. The clinical effects of ropivacaine in epidural anesthesia seems 
to be comparable to that of bupivacaine for sensory blockade. However, ropivacaine 
at equal concentrations produces less motor blockade than bupivacaine. These find-
ings are related to the physicochemical properties of these local anesthetics. Moreover, 
ropivacaine seems to have a greater margin of safety than bupivacaine. 
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Samenvatting en conclusies 
HOOFDSTUK ι beschrijft het doel van de studies van dit proefschrift met de titel: 
Ropivacaine versus bupivacaine, karakteristieken en klinische aspecten in lumbale 
epidurale blockade. 
HOOFDSTUK 2 geeft een korte beschrijving van de historie, fysiœchemische eigen-
schappen en werkingsmechanismen van lokale anesthetica. Omdat de fysicochemi-
sche eigenschappen van lokaal anesthetica, het moleculair gewicht, de vetoplosbaar-
heid, de pk en de eiwit binding, verantwoordelijk zijn voor het klinisch profiel van 
deze farmaca, worden deze uitvoerig beschreven. 
HOOFDSTUK З beschrijft de strukturclc verschillen tussen ropivacaine en bupivacaine. 
Met behulp van röntgen-diffrakde technieken is getracht de driemensionale struk-
tuur van de aktieve vormen van ropivacaine en bupivacaine inzichtelijk te maken. Na 
een korte inleiding betreffende deze techniek, worden de resultaten van deze experi-
mentele studie besproken. Hoewel ropivacaine en bupivacaine slechts verschillen in 
een CH3 groep, is de molekulaire pakking verschillend. 
In HOOFDSTUK 4 worden aan de hand van een literatuur studie, de cardiovasculaire 
effekten van de epidurale blokkade besproken. Cardiovasculaire veranderingen na 
epidurale blokkade zijn gerelateerd aan het type en de dosis van het toegediende lo-
kaal anestheticum, de toevoeging van vasoaktieve farmaka, de uitbreiding van het 
sympatisch blok en de cardiovasculaire status van de patient. 
HOOFDSTUK 5 beschrijft de techniek van niet invasieve monitoring met behulp van 
elektrische bio-impedantie. Basale principes van het circulatoire systeem worden be-
sproken. Historische hoofdpunten en de ontwikkeling van de mathematische formu-
le om het slag volume te bereken op basis van de ritmische variatie in thoracale elek-
trische weerstand, geïnduceerd door fluktuaties in de doorsnee van de grote vaten en 
de bloedstroom door deze vaten, wordt uiteengezet. 
HOOFDSTUK 6 beschrijft de hemodynamische effekten bij epidurale blokkade na toe-
diening van bupivacaine met en zonder adrenaline. Hemodynamische veranderingen 
traden binnen de г tot 4 minuten op. Hartminuut volume, slag volume en eind dia­
stolisch volume namen toe in de adrenaline groep. De verschillen worden verklaard 
door de vasoaktieve effekten van adrenaline. 
HOOFDSTUK 7 geeft een overzicht van de hemodynamische effekten bij lumbale epi­
durale blokkade met ropivacaine en bupivacaine beide met adrenaline. De gevonden 
hemodynamische verschillen zijn gerelateerd aan de vasoaktieve eigenschappen van 
ropivacaine. 
129 
HOOFDSTUK 8 behandelt een experimentele studie in ratten, waarbij de inhibitie van 
de terugtrek respons na epidurale en intrathccalc toediening van ropivacaine en bupi-
vacaine gemeten wordt. Verschillende experimentele modellen worden gebruikt om 
de werkzaamheid van lokaal anesthetica te evalueren. Het model gebruikt in deze stu-
die biedt de mogelijkheid tot weergave van graduele metingen. Na epidurale en in-
trathecale toediening, is ropivacaine minder potent in de zin van het onderdrukken 
van de terugtrek respons na het geven van een pijnprikkel. 
HOOFDSTUK 9 beschrijft een open multicenter studie waarin de klinische werkzaam-
heid van drie verschillende concentraties (0.5%, 0.75% en 1.0%) ropivacaine na epi-
durale toediening geëvalueerd wordt. De tijden die het begin van de blokkade aange-
ven, waren niet verschillend bij de 3 verschillende concentraties. De graad en de duur 
van de motore blokkade nam toe met oplopende ropivacaine concentratie, alsmede 
de analgesie duur. De studie toonde aan dat ropivacaine een effektief, lang werkend 
lokaal anestheticum is, wanneer het bij mensen epiduraal wordt toegediend. 
HOOFDSTUK 10 beschrijft de blokkerende werking van bupivacaine 0.75% en ropi-
vacaine 0.75% na epidurale toediening bij 43 patiënten. De tijden van het begin van 
de sensorische blokkade en de maximale hoogte van blokkade zijn niet verschillend in 
beide groepen. De motore blokkade is minder in de ropivacaine groep ten opzichte 
van de bupivacaine groep. De analgesie duur ter hoogte van het thoracale segment 10 
is korter in de ropivacaine groep. Analgesie voor chirurgie is in beide groepen goed. 
Conclusies 
Epidurale blokkade heeft een grote populariteit verworven om goede chirurgische 
anesthesie en postoperatieve analgesie te verschaffen. Dit is het gevolg van de ontwik-
keling van lokaal anesthetica met lange werkingsduur en goede sensorische blokkade. 
Bupivacaine was het eerste lokaal anestheticum welke de eigenschappen van een 
acceptabele inwerkingsduur, lange werkingsduur, diepe blokkade en scheiding tussen 
sensorische en motore blokkade verenigde. Echter, er bestaat een aanzienlijke be-
zorgdheid met betrekking tot de ongunstige cardiovasculaire effekten na toevallige in-
traveneuse toediening van bupivacaine. 
Ropivacaine is een nieuw lokaal anestheticum, waarvan is aangetoond dat het 
minder toxisch is vergeleken met bupivacaine. De klinische effekten van ropivacaine 
bij epidurale toediening, zijn vergelijkbaar met die van bupivacaine voor sensore 
blokkade. Echter ropivacaine veroorzaakt minder motore blokkade bij gelijkwaardige 
concentraties in vergelijking met bupivacaine. Deze bevindingen zijn gerelateerd aan 
de physicochemischc eigenschappen van deze lokaal anesthetica. Bovendien blijkt ro-
pivacaine een grotere veiligheidsmarge te hebben dan bupivacaine. 
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STELLINGEN 
behorende bij het proefschrift 
Ropivacaine versus bupivacaine 
characteristics and clinical aspects in lumbar epidural blockade 
H E M . KERKKAMP 
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1 
De fysicochemische eigenschappen van een lokaal anestheticum, bepalen mede de 
klinische werkzaamheid. 
2 
Hemodynamische metingen kunnen op een veilige, betrouwbare en niet invasieve 
wijze verricht worden met behulp van thoracale bioimpedantie monitoring. 
3 
Adrenaline toegevoegd aan epiduraal toegediende langwerkende lokaal anestheti-
ca, is meer van invloed op de hemodynamiek van de patiënt dan op de werkings-
duur van het anestheticum. 
4 
Door de uitgesproken differentiële zenuwblokkade, is epiduraal toegediend ropi-
vacaine geschikt voor obstetrische en postoperatieve epidurale pijnbestrijding. 
5 
Voor snelle en accurate hemoglobine bepalingen is de hemocue zeer geschikt. 
6 
De dextraan dilutietcchniek is een betrouwbare methode voor het bepalen van het 
circulerend plasmavolume. 
7 
Ook voor huisartsen dient een stage anesthesiologie in het curriculum opgenomen 
te worden. 
8 
Gezien het feit dat absoluut en verhoudingsgewijs de sterfte van mensen tijdens 
anesthesie geringer is dan de sterfte in het algemeen, zou het interessant zijn te on-
derzoeken of een toestand van anesthesie een positieve invloed heeft op de levens-
duur. 
9 
Het gezegde: schoenmaker houd je bij je leest, geldt ook ten aanzien van de keuze 
van de anesthesie techniek. 
10 
Anesthesiologie is een kind van de tijd, de budgetering maakt het een kind van de 
rekening. 
11 
Een consensus betekent dat iedereen afspreekt iets collectief te zeggen, wat nie-
mand individueel gelooft. Abba Eban. Uit: From Beirut to Jerusalem, Thomas 
Friedman. 
12 
Automobiliteit is belangrijker dan een automobiel voor iedereen. 



